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1.1 Drugs in Modern Medicine  
 
The treatment of diseases has seen a broad development over the last decades. A variety of 
different treatment options exist, spanning from small molecule drugs, over liposomal drug 
formulations[1] and polymer drug conjugates[2] to therapeutic proteins. They all differ 
regarding their active pharmaceutical ingredient (API) and the formulation of the drug, such 
as in the form of a tablet, a solution, an aerosol, a cream or an injectable solution. These 
formulations are considered as a combination of the API and any adjuvant substances, such as 
tablet filler, solvent, surfactant and preservatives. Depending on the characteristics of the API 
as well as its formulation, the administration to the body is determined. There are four broad 
classes of administration routes for drugs, namely oral, local, inhalative, and intravenous 
administration (Figure 1A).[3] The most common route is the oral route via tablets and the 
most convenient one in terms of patient compliance. However, the type of administration is 
tied to the specific drug/API and the disease that is treated. Local treatment of diseases is 
convenient for patients as well, because eye drops, and creams can be easily applied, and most 
drugs only act in the specific area in which they are applied.[4] This limited drug uptake into 
systemic circulation is one of the advantages of topical applications. A lot of side effects of a 
drug come from the systemic distribution of drugs and thus the uptake into tissues that are 
unrelated to the disease. If, however, a systemic distribution is necessary, oral drug 
administration is usually the preferred route. 
One drawback of orally administered drugs is that they are taken up in the small 
intestine, which directly supplies the liver with any molecules reaching the blood stream. 
Liver enzymes, such as the cytochrome P450 system, metabolize many endogenous and 
foreign substances. This has the aim of detoxification of certain substances or to increase 
water solubility and thus the excretion rate from the body.[5] This poses a problem for the oral 
treatment route, as a lot of drugs get metabolized within the first contact with the liver and are 
most commonly inactivated or modified in a way that leads to a faster excretion. This effect is 
called the first pass effect and leads to the adjustment of the dose that must be administered to 
the body. As a large percentage of drug is inactivated, the amount of API must be increased 
per dose to reach the desired concentration within the blood stream. However, with some 
drugs the metabolism within the body is used as an advantage, because the compound that is 






Another aspect to consider is that some APIs do not have a matching 
hydrophobicity/hydrophilicity balance. This is corresponding to a too high or too low 
octanol/water distribution coefficient, also called logP value. It means they are either too 
hydrophilic to cross the lipid membrane of the small intestines cell lining or so hydrophobic 
that they are trapped within the membrane and cannot easily pass on into the blood stream.[7] 
The amount of drug that reaches the blood stream compared to the total amount of drug that 
was administered is called the bioavailability of the drug.[8] Due to the insolubility and the 
instability under acidic conditions such as stomach acid of some drugs, as well as slow uptake 
within the intestine, the bioavailability of a lot of orally administered drugs is quite low.[9] 
Some drugs are insoluble in water or not taken up at a reasonable rate that the only choice is 
to administer them intravenously or through inhalation into the lungs. The bioavailability of 
an intravenously administered drug is therefore 100%, as all the compound reaches the blood 
stream.  
From this point on, the compound is distributed all over the body and depending on 
the affinity of the API towards certain tissues or cell types, it accumulates there. However, 
after a certain time every water-soluble compound will also be excreted from the body via the 
kidneys if the molecular mass is below the renal threshold. This threshold lies at a molecular 
mass around 45 kDa or an aggregate diameter of 5.5 nm. Below this threshold, molecules are 
easily excreted.[10–12] 
The characteristics described above can be combined into the concept of LADMET[13], 
meaning liberation, administration, distribution, metabolism, excretion, and toxicity of a drug. 
All these different points must be considered when applying new drugs to the market. Failing 
to meet the requirements in one of these areas can lead to the end of the development of a 
certain drug or the discontinuation of a clinical trial. Modern research aims to optimize every 
aspect of the LADMET concept for the specific disease that must be tackled. The term 
liberation in this context means the release of the API from tablets, as well as from any drug 
delivery vehicle that was used. This especially plays a role in the use of nanocarrier systems, 
which will be discussed in a later paragraph.  
Distribution of a drug is mostly dependent on the affinity of the drug molecules to the 
different tissue types. However, directly after administration the drug is distributed into all 
kinds of tissues and only after that it accumulates in specific tissues. Usually, small molecular 
weight drugs do not actively target tissues, but are passively accumulated according to their 
lipophilicity. The aim of most therapeutic approaches is to make a drug formulation that 






receptors, or by taking advantage of the physical properties of some diseased cell types, such 
as cancers. In these cancerous tissues the blood vessels are malformed and the junctions 
between epithelial cells are missing, leading to a fenestration of the blood vessel wall. Thus, 
uptake of larger particles becomes possible, compared to healthy tissues. This opens the 
opportunity for new therapeutic options, where larger carrier systems transport the drug 
preferentially into the tumor tissue. Due to an impaired lymphatic system, the carriers are 
trapped within these tissues and accumulate. Thus, a high local concentration of drug is 
achieved. This effect is called the enhanced permeation and retention effect (EPR-
effect).[1,14,15] An overview on the aspects of LADMET, as well as active and passive 
targeting, and immune clearance are shown in Figure 1.  
 
 
Figure 1. Overview on different aspects of the LADMET concept. A) pathways of drug administration, 
metabolism and excretion, B) enhanced permeation and retention effect (EPR)-effect in tumorous tissue, immune 
clearance by the mononuclear phagocyte system (MPS) and cell uptake by active targeting. Reprinted from 
Journal of Controlled Release 2014, 187 with permission from Elsevier.[1] 
 
In order to overcome the hurdles that exist in the context of a treatment with small 
molecules, research has focused on solving the specific issues of non-targeted distribution in 
the body, increasing the local concentration of drugs, increasing the plasma circulation time 
by lowering the excretion rate, and reducing side effects and potential toxicity. One promising 








1.1.1 Polymer Drug Conjugates 
 
A lot of problems within the LADMET concept can be tackled by using a polymer backbone 
to which drug molecules are covalently connected to. These polymer-drug conjugates have 
the advantage of providing a high local drug concentration as a lot of individual drug 
molecules can be attached to one polymer chain. Furthermore, by addition of cell specific 
targeting ligands, active targeting to the diseased cells becomes possible.[16–19]  
 In order to release the drug at the targeted tissue, cleavable linkers between drug and 
polymer can be introduced. These linkers between the polymer backbone and the drug can be 
cleaved by or respond to certain specific environmental conditions, including acidic[18,20], 
reductive[21] or oxidative[22] conditions. This approach leads to enhanced bioavailability and 
protection of the conjugated drugs during circulation, as well as significantly prolonged 
excretion times. The design itself corresponds to a prodrug that releases its API upon 
environmental stimuli.  
 The polymer backbone can comprise different types of polymers. Polymer drug 
conjugates have been prepared from e.g. polyethylene glycol (PEG)[23], polyvinyl alcohol 
(PVA)[24], polylactic acid (PLA)-PEG copolymers[25], alginic acid[26,27], as well as natural 
polymers such as heparin[28] or even the protein albumin[29] The polymer backbone, however, 
is also the biggest hurdle to approval, as most polymers cannot be obtained in a monodisperse 
fashion. Another problem to solve is the accumulation of polymer within the body, as well as 
potential toxicity of some of the polymer degradation products. Functional groups are 
mandatory in order to be able to conjugate the desired drug. A variety of different groups can 
be used as cleavable linkers, such as acetals or hydrazones for acid cleavable systems. In the 
majority of studied polymer-drug conjugates, drugs such as the anticancer drug doxorubicin, 
but also a prodrug of the anticancer drug cisplatin were used, among others.[18]  
 
1.1.2 Therapeutic Proteins 
 
Another broad class of therapeutics, apart from small molecules, is the class of therapeutic 
biomolecules. This includes antibodies[30], hormones, cytokines, regulatory peptides, proteins, 
and growth factors. Many different types of diseases are treatable with these kinds of 
therapeutics, however, only quite recently, biotherapeutics emerged on the market.[31] With 
the advancements in genomics the straightforward preparation of these biomolecules in large 






tissues, which comes with the risk of contamination, was the only option.[32] Additionally, 
these approaches were time consuming and low yielding. 
 The great advantage of biotherapeutics is that most members of the class are ligands to 
one, or only very few receptors within the body. This makes them highly specific with very 
little side effects from unspecific interactions with other receptors. The specificity is also the 
reason why, for example, antibodies can be used as the active targeting option in polymer 
drug conjugates, as they lead to the accumulation within the tissues and cells that present their 
corresponding antigen on the cell surface.[17,33]  
 Besides the advantages of antibodies and proteins, they all suffer from a limited 
amount of administration options. Most proteins do not survive the acidic conditions in the 
stomach. Furthermore, they are not readily taken up in the small intestine. In most cases, the 
only option is to administer the protein intravenously, which can only be performed by 
medical professionals. However, exceptions exist, e.g. in the case of the small peptide insulin, 
which can be applied by the patient via abdominal injection.[34] 
 In the circulatory system, additional challenges of biological therapeutics have to be 
considered. Some compounds are easily recognized by the immune system, which leads to 
inactivation by the mononuclear phagocyte system (MPS) and thus a loss of function and the 
requirement for higher doses.[35,36] Furthermore, a lot of therapeutic proteins are small and 
below the renal threshold of 45 kDa, which leads to fast excretion and low plasma half-lives. 
As with small molecules, a major strategy to increase plasma half-lives and to reduce immune 
recognition for proteins is the conjugation of the protein to a polymer backbone. The 
conjugation leads to an increased overall molecular weight of the modified protein, which is 
above the renal threshold, thus prolonging plasma circulation. The gold standard, which is 
today most commonly used for this purpose, is the polymer polyethylene glycol (PEG).[37–41] 
It is usually covalently bound to the protein at a part of the structure which optimally should 
not affect the binding affinity between protein and receptor. The conjugation of one PEG 
chain, as well as multiple PEG chains is possible. The conjugation can be achieved by 
unspecific modifications of free amine groups of lysine side chains. However, the site-specific 
modification of certain amino acid residues is preferred, due to the control over protein 
function. By site specific modification, one can assure that parts of the protein are conjugated 
that do not have an influence on the active site of the protein. Through genetic modification, 
an unnatural amino acid can be incorporated at the desired point in the sequence.[40] However, 






compared to the natural protein. An example for a PEGylated protein on the market is 
Oncaspar® which is PEGylated asparaginase.[42]  
 However, recently it became apparent that PEG can induce an immunogenic response, 
although it has quite a low overall toxicity. Antibodies against PEG have been found in 
patients treated with PEGylated proteins, which in some cases lead to a reduced therapeutic 
response because of fast elimination of the conjugate. In more serious cases, the immune 
response, can lead to an anaphylactic shock, which actively threatens the life of the patient if 
not treated immediately. These reasons led research to focus on alternatives for PEGylation of 
therapeutic proteins. This includes alternative polymers for conjugation, as well as completely 
different approaches, such as physical encapsulation within polymer networks.[2,43–45]  
 
1.2 Biocompatible Polymers 
 
For any application in the body, polymers must have certain properties. First, they should not 
show any toxicity towards target tissues, if they are used in implants or prosthetics. Second, if 
they are directly applied to the blood stream, as in the case of PEGylated proteins, they also 
should not have any adverse effects. Polymers that are non-toxic in the body are said to be 
biocompatible, however the definition of biocompatibility is a topic of discussion. One of the 
most detailed definitions comes from WILLIAMS. He states: “Biocompatibility refers to the 
ability of a biomaterial to perform its desired function with respect to a medical therapy, 
without eliciting any undesirable local or systemic effects in the recipient or beneficiary of 
that therapy, but generating the most appropriate beneficial cellular or tissue response in that 
specific situation, and optimizing the clinically relevant performance of that therapy.”[46] 
The definition he proposes is quite complicated, however, this shows that the concept itself is 
not clearly defined. In general, one can focus on the absence of toxic effects in the target 
tissues, as well as on systemic toxicity.  
 Another big aspect in this context is biodegradability. Biodegradability means that a 
material can be broken down by processes that happen within living systems. This 
encompasses metabolic activity, as well as degradation of bulk material by microorganisms. 
Biodegradability is especially important when it comes to the application of synthetic 
polymers within the body. Any polymeric material that enters the blood stream must be 
excretable from the body. However, if the molecular weight of the compound is above the 
renal threshold, excretion is severely hindered, thus, leading to accumulation in organs, which 






under the physiological conditions into non-toxic fragments, which are smaller than the renal 
threshold and can therefore be easily excreted by the body.[47,48] 
 This degradability can be achieved by linking polymers with biodegradable linkers or 
using polymers that have an intrinsically biodegradable backbone. A few examples of 
biomedically relevant polymers will be discussed in the following section. 
 
1.2.1 Medically Relevant Polymers 
 
Different synthetic and natural polymers have been considered for biomedical applications. 
Very prominent examples of synthetic polymers include PEG, polylactic acid (PLA), 
polycaprolactone (PCL), copolymers of lactic and glycolic acid (PLGA). Additionally, natural 








Figure 2. Selection of synthetic and naturally occurring polymers, relevant in biomedical research and 
application. Functionalizable groups are shown in red. Biodegradation conditions are given for every example.  
 
 There have been many studies on the above-mentioned polymers. This can be 
attributed on one side to the synthetic accessibility, as well as on the other side to the 
biocompatibility of these polymers. PEG, as mentioned, is the gold standard for the 
conjugation to proteins, but is also widely used as a linker molecule. It is obtained through 
either cationic or anionic ring opening polymerization of ethylene oxide. Polymers with 
narrow polydispersity values can be obtained in this fashion. The polymer itself is hydrophilic 






discussed. Furthermore, PEG is not biodegradable and only functionalizable at the terminal 
groups.[39,41,49]  
 PCL as a polymer is obtained through ring opening polymerization of caprolactone. 
The polymer itself is quite hydrophobic so it is usually used as a copolymer with more 
hydrophilic monomers or blocks.[50] This hydrophobicity has the advantage of strong van-der-
Waals (vdW) interactions with hydrophobic drugs, which gives it the opportunity to 
physically bind these drugs in block copolymers, where PCL is the hydrophobic block. It is 
inherently biodegradable, due to the ester bonds throughout the polymer backbone. Here, the 
main mode of degradation is the enzymatic cleavage of the ester by esterases. As a result, it 
does not bioaccumulate and can be excreted from the body after the initial polymer is 
degraded to fragments below the renal threshold.[51]  
 PLA and PLGA show excellent biocompatibility and degradability when used as an 
implantable material.[50,52,53] After some time, natural hydrolysis leads to the polymer 
breakdown with non-toxic degradation products such as lactic and glycolic acid. However, for 
use as a conjugatable polymer to proteins, they are too hydrophobic. Furthermore, the 
functionalization is limited to the terminal groups. 
 Examples for natural polymers are e.g. chitosan and alginate, both being 
polysaccharide derivatives. Chitosan is a linear β-(14)-linked D-glucosamine which is 
randomly linked to N-acetyl-D-glucosamine units. It is derived from the shell of shrimp and 
other crustaceans by treatment of the chitin (fully N-acetylated D-glucosamine) with sodium 
hydroxide. This gives rise to different polymers with varying degree of acetylation. It is 
highly hydrophilic and biocompatible and used as a wound dressing polymer and scaffold 
material for nanoparticles. The material is also inherently biodegradable, as the 
polysaccharide can be broken down by lysozyme to glucosamine and is thus absorbed and 
metabolized by the body.[21,54,55] 
 Alginic acid or the sodium and calcium salt, called alginate is a linear block 
copolymer of β-(14)-linked D-mannuronate and α-(14)-linked L-guluronate, and is 
derived from the cell walls of brown algae and some bacteria. It is also highly hydrophilic and 
has the property to form polymer networks upon treatment with e.g. calcium-ions. This makes 
it a good scaffold material for the encapsulation of living cells. The number of functional 
groups enables further modification, e.g. the addition of growth factors for cells. However, the 
polymer itself is not degradable by humans as they lack the necessary enzyme.[26,27,55–57] 
 All these polymers have advantages and disadvantages and there is a variety of other 






PEG, as one of the wildly used polymers, new alternatives are needed. One of these 
alternatives is Polyglycerol, which will be discussed in the next section.  
 
1.2.2 Linear and Dendritic Polyglycerol 
 
Structurally very similar to PEG with its polyether backbone is the linear version of 
polyglycerol shown in Scheme 1. 
 
 
Scheme 1. Simplified reaction scheme for the polymerization of glycidol and acetal protected glycidol to yield 
dendritic polyglycerol (left) and linear polyglycerol (right), respectively. Initiator molecules are shown in blue, 
functionalizable groups are shown in red.  
 
 Instead of using ethylene oxide to produce PEG, one can use a derivative of ethylene 
oxide, glycidol, to produce linear or hyperbranched polyglycerol, that are structurally related 
to PEG. 
 Monomer activated ring opening polymerization of a protected glycidol derivative 
yields linear polymers with defined end groups, a polyether backbone and side chains with 
protected hydroxy groups. In the case of acetal-protected glycidol, the resulting polymer can 






polyglycerol (lPG) and structurally very similar to PEG.[44,58,59] However, it possesses one 
hydroxy group per monomer at the side chains, which makes it even more hydrophilic than 
PEG. Side chain functionalization becomes possible, additionally to the terminal 
functionalization that is available for PEG. These numerous hydroxy groups influence the 
polymer structure in solution and could have an influence on the evasion from the MPS 
clearance, offering a stealth effect for a coupled protein. It is anticipated that lPG, due to its 
higher hydrophilicity, will not induce an immunogenic response and prevent the formation of 
anti-lPG antibodies.  
 The anionic ring opening multi-branching polymerization of unprotected glycidol 
leads to the hyperbranched version of polyglycerol, also called dendritic polyglycerol (dPG) 
which can be seen in Scheme 2.[60–62] It is a highly hydrophilic polymer and possesses around 
one hydroxy group per monomer. Thus, dPG has a very biologically inert surface which 
prevents unspecific protein adsorption and renders it quite biocompatible and non-toxic. The 
vast number of functional groups can be used for post-functionalization, which makes it an 
ideal platform for many applications.[63–66] It has been used as a hydrophilic core for core-
shell structures[67], as a polymeric support for catalysts[68], as scaffold material for polymeric 
networks[64,66], and many more. Post-modification of the hydroxy groups to sulfate groups 
yields potent L-selectin-inhibitors and thus, immune-modulating polymers.[69–72] Due to the 
mentioned properties it is a highly versatile polymer exhibiting the needed properties for the 
use in biomedical applications. However, it lacks inherent biodegradability, as the polyether 
backbone cannot be broken down by the body. Therefore, only polymers with molecular 
weight below the renal threshold can in general be used for applications, as larger polymers 
will not be excreted easily by the body and accumulate. Degradable alternatives, including a 
copolymer of glycerol and caprolactone, have been developed recently and show promising 
properties as nanocarriers for hydrophobic drugs.[73]  
 
1.3 Nanocarrier Systems 
 
The requirements for a successful nanocarrier are high. Several criteria must be met in order 
to have the optimal nanocarrier. These criteria include a prolonged blood circulation of the 
drug, the ability to accumulate via active or passive targeting in the relevant pathological 
zone, responsiveness to local stimuli, such as pH and/or temperature changes, resulting in 
accelerated or burst drug release. Furthermore, a nanocarrier has to allow for an effective 






biodegradable.[74] As mentioned before, a way to overcome low solubility of some drugs or 
rapid clearance is to covalently attach them to a polymer backbone as seen for polymer-drug 
conjugates. Analogously, the covalent attachment of PEG, or in general, polymers to 
therapeutic proteins is also a kind of nanocarrier system, although one can debate, if the 
polymer in protein-polymer conjugates counts as a carrier. Nevertheless, the polymer 
increases the blood circulation time and reduces the immune clearance, as well as the renal 
clearance. 
 Besides polymer-drug conjugates, there are many more ways to deliver a drug or 
protein to the side of action and over the last decades a variety of different systems have been 
developed. These nanocarriers can be divided into different groups, including lipid-based, 
inorganic, polymeric, and protein based nanocarriers, depending on the material that they are 
made of. The four main groups can be seen in Figure 3. 
 
 
Figure 3. Different groups of nanocarrier systems divided into the class of material that they are made of, a) 
nanocarrier systems, b) loading methods of drugs/proteins with nanocarriers, reprinted from Chem. Soc. Rev., 
2011, 40, 3638–3655, with permission from Royal Chemical Society.[75] 
 
 There are three methods of loading for nanocarriers. First, the direct conjugation of 
drug to the carrier. For this method the most prominent example is the polymer-drug 






molecules or proteins to the carrier surface. This approach works very well for inorganic 
carriers, such as carbon nanotubes and graphene, where hydrophobic drugs with aromatic ring 
system are adsorbed to the aromatic surface via π-π stacking interactions. Another prominent 
example is protein nanocarriers that can bind drugs to the protein surface. Ionic interactions 
between a poly-ionic species such as a charged polymer and a charged drug are also possible 
in this context.[75] 
 The third loading method involves physical entrapment within the structure of the 
nanocarrier. The interactions that keep the drug within the carrier are in this case either 
hydrophobic interactions between parts of the carrier and a drug, or physical entrapment 
within a network, which strongly hinders diffusion of the encapsulated drug molecule. This 
method is one of the most commonly used, as the drug is not chemically altered and thus 
completely keeps its biological effect.  
 
1.3.1 State of the Art 
 
As of 2012, there were around 100 nanomedicines available on the market that were FDA 
approved.[34,42] The most common nanocarriers in this regard are liposomal formulations of 
small molecules, such as the anticancer drug doxorubicin. Liposomal formulations work by 
physical entrapment of a drug within the liposomal aggregates of a lipid. Hydrophilic drugs 
and hydrophobic drugs alike can be encapsulated at the same time. Hydrophobic drugs are 
incorporated in the hydrophobic bilayer of the alkyl chain part of the lipids, while hydrophilic 
drugs are encapsulated within the inner water filled cavity of the liposomes. The size of the 
liposomes makes it possible to take advantage of the EPR effect, resulting in enhanced uptake 
into tumors, as compared to normal tissues. The advantage of these formulations is the 
increased solubility of the drug, a much higher local concentration within the carrier, and 
decreased side effects due to the smaller amount of free drug. Examples for approved 
liposomal drug formulations include Doxil®, which is liposomal doxorubicin. It was approved 
by the FDA in 1995 and is used for the treatment of metastatic ovarian cancer and AIDS-
related Kaposi´s Sarcoma.[42,76,77]Other nanocarriers based on protein drug conjugates are 
available such as Abraxane®, in which the anticancer drug paclitaxel is bound to albumin 
nanoparticles of around 130 nm. It is used for the treatment of metastatic breast cancer, lung 






 The class of PEGylated proteins includes a lot of different marketed products, one of 
which is Oncaspar®, a PEGylated version of the protein L-asparaginase. It is used in the 
treatment of acute lymphoblastic leukemia, and chronic myelogenous leukemia.[78] 
 However, currently there is no example for polymeric nanocarriers on the market, 
other than protein-drug conjugates and liposomal formulations.[42] A lot of research effort has 
been put into the development of polymeric micelles, unimolecular micelles, graphene, 
carbon nanotubes, and nanogels. The reason for the absence of examples of these nanocarrier 
types includes either toxicological issues, due to the problem of polydispersity of the 
polymeric materials used, or an enhanced accumulation of the nanocarriers in organs. 
Nevertheless, numerous promising examples for nanocarriers that have the potential to reach 
the market, have been reported in the last years.[34,78] Here one approach is the encapsulation 
of drugs in unimolecular micelles. 
 
1.3.2 Unimolecular Micelles 
 
The group of nanocarriers that are based on polymers offers a wide variety of different 
structures which depend on the type of polymer that is used. Block copolymers, consisting of 
a hydrophobic and a hydrophilic block, for example, can be used for the encapsulation of 
hydrophobic drugs. This kind of polymers can form polymeric micelles in aqueous solution, 
with an inner hydrophobic core and an outer hydrophobic shell. Within the hydrophobic core, 
hydrophobic drugs can be encapsulated by physical interaction of the hydrophobic block with 
the drug. Upon cell uptake these micelles can release their payload. However, premature 
disintegration of the micelle limits the applicability of this carrier. Micelles are only stable 
above a certain critical concentration, also called critical micelle concentration (CMC).[79–81] 
If this concentration is too high for a certain block copolymer then the micelles fall apart 
when they encounter the blood stream, as they are quickly diluted below the CMC. This leads 
to premature disruption of the micelles and thus drug release.[82] 
 An alternative to the physical stabilization of micelles is the use of core shell 
structures, especially core multi-shell structures. In these cases, the polymer does not form 
micelles in solution, but itself has properties of a micelle. Branched polymers or dendritic 
systems are suitable for these applications. Core-shell structures are constructed by the design 
of a hydrophobic polymer core which is then modified with a hydrophilic polymer to yield a 
unimolecular micelle that can encapsulate hydrophobic guests and still is water soluble and 






in such a fashion. Here, for example, a hydrophilic hyperbranched core such as dPG can be 
used and covalently modified with a hydrophobic chain, such as a PCL block or a fatty acid, 
which is then capped with a PEG or lPG chain. Thus, a core multi-shell structure is formed 
with a hydrophilic dPG-core, a hydrophobic shell and a solubilizing outer shell of PEG. These 
unimolecular systems can encapsulate hydrophobic drugs within their PCL shell.[83–85]  
 However, multi-shell systems are generally not very suitable for the encapsulation of 
therapeutic proteins, as the detergent nature of some of the micelles can denature the protein 
structure. Many proteins are also large compared to the unimolecular micelles which means 
that there is no way for the protein to be encapsulated within the shell structure of the carriers. 
The only way would be that the carriers as a whole surround the protein and form protein-
carrier aggregates. 
 Proteins need a sufficiently large nanocarrier, which does not have detergent-like 
properties and provides a close to natural environment for the protein. By this, a protein can 




1.4 Nanogels as Drug Delivery Systems 
 
Nanogels are highly water-swollen polymer networks in the size range of 10 to 1000 nm.[56,86] 
The gels can be formed by physical entanglement of polymer strands, chemical crosslinking, 
supramolecular interactions, electrostatic interactions, and coordinative bonding.[87,88] This 
shows the vast variety of possibilities to obtain such polymer networks. As the nanogels are 
water swollen, the polymers used are usually hydrophilic polymers such as PEG, 
poly(methacrylate), chitosan, alginate, poly(vinyl alcohol), lPG, and dPG. The porous nanogel 
network can be tuned regarding polymer density, pore sizes, surface charge and degradability 
by the use of different scaffold material, as well as crosslinking moieties. The size of the 
nanogel has a big influence on cell uptake behavior, as cell uptake is usually quite hindered 
above around 100 nm.[89]  
 Depending on the polymers and crosslinkers used, the gel network can load a variety 
of biomedically relevant payloads. If hydrophobic groups are used within the network, 
hydrophobic drugs can be encapsulated.[90] Positively charged nanogels, based on 
polypropylene imine (PPI) can load negatively charged ribonucleic acid (RNA) for gene 






proteins. The gel network of hydrophilic and inert polymers provides an optimal environment 
for protein structure preservation and shielding from immune recognition. 
 
1.4.1 Stimuli Responsive Nanogels 
 
Nanogels that show enhanced or even burst drug release are desired, as they allow for a 
temporal and spatial control over the release of the payload. Nanogels that are made 
completely from hydrophilic polymers without any hydrophobic blocks cannot efficiently 
encapsulate hydrophobic drugs, as there are not strong enough interactions to keep the drug 
within the network. Even if a hydrophobic block exists and interactions keep the drug, there is 
a constant loss of drug to the environment due to diffusion. Thus, gels will slowly lose their 
cargo over time. This slow, constant release can be desirable, however, in most cases a non-
leaching carrier is wanted that releases the payload upon certain environmental stimuli. This 
has the advantage that toxicity in healthy tissues can be reduced if the stimulus exists within 
the diseased tissue but not in the healthy tissue. Furthermore, if the stimulus is not 
environmental, but external, the functionality of the carrier increases even more. 
Environmental stimuli can be for example, changes in pH, ion strength, and redox 
environment, while external stimuli can be temperature changes, magnetic fields, ultrasound, 
and light.[94–96] Stimuli-responsiveness must be introduced into the nanogel by using polymers 
with certain functional groups that react to the change in environmental conditions or the 










Scheme 2. Examples for functional groups or polymers that exhibit stimuli-responsiveness. Behavior of the 
corresponding nanogels is shown on the right.  
 
Thermo-responsive systems can be used to target tumors that are near the body surface. When 
heat is applied from the outside of the skin, the temperature rises above the lower critical 
solution temperature (LCST) of the thermo-responsive polymers, which triggers the collapse 
from the extended water-swollen state to the aggregated insoluble state of the polymer. 
Together with water, the drug is expelled from the carrier.[97–99]  
 In pH-responsive gels, amine groups or carboxy-groups are usually used. These are 
protonated or deprotonated at certain pH values. Amines, for example, are protonated at low 
pH values and gain net electric charge. As more groups within the gel network are protonated, 
the network draws in more water and expands, thus creating bigger pores and a higher rate of 
diffusion, which leads to an accelerated drug release.[100] Other stimuli such as magnetic fields 
can guide nanogels that incorporate magnetic nanoparticles[17,101].  
However, all these stimuli and responsive groups usually do not lead to a degradation of the 
nanogel. Degradation is desired, as nanogels are in a size range where excretion through the 
kidneys is not possible. This means that after drug release they can accumulate and cause 
toxicity. Biodegradable nanogels are thus needed for real biomedical applications. 
 
1.4.2 Degradable Nanogels 
 
Degradable nanogels also respond to stimuli, however, the response is the degradation of the 






a reduced pH-value which is found in tumor tissues (pH 6-7), inflamed tissues (pH 6-6.5), 
endosomes (pH 5.5), and lysosomes (pH 4.5)[96]. Another commonly exploited stimulus is the 
reductive environment within cells compared to blood plasma. This reductive environment is 
due to the presence of free glutathione (GSH) within the cells. Furthermore, the level of GSH 
in tumor cells is higher compared to normal cells, enabling the specific treatment of tumor 
cells.[21,102,103] Some examples of cleavable linker groups are shown in Scheme 3.  
 
 
Scheme 3. Selection of linker moieties that are cleaved under certain environmental or external stimuli. 
Fragments are shown in different colors. 
 
As mentioned, the GSH level in tumor cells is higher than in normal cells, which leads to the 
reductive cleavage of disulfide bonds. Thus, this is a commonly used motif for redox-sensitive 
nanocarriers. One example are enzymatically crosslinked nanogels, based on linear 






 For tumor treatment of the skin, one can use light-sensitive nanogels, were the linking 
groups degrade upon exposure to certain wavelengths of light, as in the case of 2-
nitrophenylesters (UV-light). KLINGER et al, for example prepared light and enzymatic 
sensitive nanogels based on polyacrylamide with acrylate-functionalized dextran that were 
degraded upon exposure to UV-light of 365 nm.[105] 
 Especially, a variety of pH-degradable nanogels have been produced in the past. Many 
different functional groups allow for degradation at endosomal or lysosomal pH values, such 
as acetals, ketals, orthoesters, imines, and hydrazones. Depending on the application, one can 
choose a suitable linker for pH-degradation. For example, CHEN et al have prepared acetal 
functionalized polyvinyl alcohol (PVA) based nanogels through UV-crosslinking. Paclitaxel 
was encapsulated and could be released at a pH of 5.[106] Cell encapsulation and release, based 
on benzacetal-functionalized microgels was shown by STEINHILBER et al.[107] 
 Slow biodegradation is achieved with esters and amides. They can be hydrolyzed at 
low pH values but at a much slower rate than acetals or imines. Therefore, long term 
accumulation is prevented by inclusion of ester or amide bonds into the polymeric network of 
nanogels. However, for many applications a fast drug release is preferred, so easily cleavable 
groups are used for a burst drug release. 
 
 
1.5 Synthetic Methods for Nanogel Preparation 
1.5.1 Conventional Methods 
 
Nanogels can be prepared through many different methods. The preparation methods can be 
divided into polymerization of monomers in a homo- or micro/nanoscale heterogeneous 
phase, physical self-assembly of polymers, crosslinking of preformed polymers, and template-
assisted nanofabrication of nanogel particles using nanolithography.[88] 
 Self-assembly of polymers leads to nanogels that are either held together by 
hydrophobic interactions if amphiphilic block-copolymers are used, or that are bound by 
supramolecular bonds between for example β-cyclodextrin and a guest molecule such as 
lauryl chains. AKIYOSHI et al. entrapped insulin within hydrogels, made by the hydrophobic 
association of cholesterol-modified pullulan.[108] GREF and co-workers, on the other hand, 
described the self-assembly of nanogels by supramolecular host-guest interactions of a β-






Some of the more common preparation methods are the mini- and microemulsion 
polymerizations of monomers or macromonomers.[14,60,105,110–115] In these methods, droplets of 
reactive monomers in the desired size range are obtained by high energy input from 
ultrasonication in miniemulsion and large amounts of surfactant in microemulsions. 
Crosslinking of the monomers in the templated droplets leads to polymer beads in the 
nanometer to micrometer range, which are dispersed in the reaction solvent. However, the use 
of ultrasonication and surfactants are quite harsh reaction conditions, so the in situ 
encapsulation of proteins is limited or even impossible and problems with surfactant removal 
can arise.[115–117] An example for the microemulsion process is the work of DESIMONE and co-
workers. Cationic PAETMAC nanogels were made by inverse microemulsion polymerization 
of 2-hydroxyethylacrylate and 2-acryloxyethyltrimethylammonium chloride in heptane, using 
PEG-bisacrylate as the crosslinker.[114] 
Templated synthesis of nanogels using soft lithography is another option to obtain 
very well-defined and almost monodisperse gels in a variety of shapes from a lot of different 
organic precursors.[88] DESIMONE and co-workers developed the PRINT method, which stands 
for particle replication in non-wetting templates. Here, particles in the range of nanometers to 
several micrometers are obtainable. This technique creates nanogels within non-wetting 
elastomeric molds, consisting of a perfluoropolyether network. This network is formed on 
patterned silicon templates by photochemically induced crosslinking of dimethacrylate-
functionalized perfluoropolyether oligomers.[118] 
Another useful method for the preparation of hydrophobic nanoparticles is the 
nanoprecipitation method, which is based on the insolubility of some growing polymers in a 
corresponding non-solvent.[119] For example, polystyrene- (PS),[120] polylactic acid, and 
copolymers of polylactic and glycolic acid (PLA/PLA-co-PGA)[119,121] nanoparticles have 
been prepared using a nanoprecipitation protocol. These nanoparticles can be used for the 
encapsulation of hydrophobic drugs. 
 
1.5.2 Inverse Nanoprecipitation for the Encapsulation of Proteins 
 
Apart from the nanoprecipitation method that produces hydrophobic nanoparticles by 
precipitation in water, the inverse case has been first described by STEINHILBER et al., where 
dendritic polyglycerol nanogels were prepared by precipitation in acetone.[122] This method 






ultrasound or any kind of surfactant is needed, which makes this a very mild method for the 
preparation of nanogels. Therefore, in situ encapsulation of therapeutic proteins is possible, 
which would be destroyed by alternative nanogel preparation methods. By this method, 
proteins were encapsulated with high efficiency and retained their functionality upon 
release.[122]  
During inverse nanoprecipitation, the macromonomers form nanoaggregates due to the 
diffusion of the solvent into the non-solvent. These aggregates are then crosslinked in order to 
obtain a stable nanogel network that is then subsequently dispersed in water. In a last step, the 
final gels are obtained by removal of acetone. 
A further improvement to the batch-wise inverse nanoprecipitation method is the 
continuous method of using a microfluidic system for the controlled synthesis of polymer 
nanoparticles. The hydrodynamic flow ensures a rapid and controllable mixing of solvent and 
non-solvent within the microfluidic channels.[119] VALENCIA et al. showed the feasibility for a 
PLGA-b-PEG copolymer in acetonitrile/water.[123] Furthermore, a flow-based approach 
enables the production of large amounts of nanogels and might be suitable for upscaling for 
biomedical applications. 
However, fast screening of conditions is done in a much easier way in the batch-wise inverse 
nanoprecipitation method, which is the reason that it was chosen for this work. 
 
1.6 Click-Type Reactions for Crosslinking 
 
The crosslinking chemistry is an important aspect when it comes to nanogel formation from 
polymeric precursors. If sensitive cargos, such as proteins has to be encapsulated, the cross-
linkable reactive groups should not react with the protein in any way. This refers to the term 
biorthogonality which was introduced as a concept by BERTOZZI in 2003. Bioorthogonal 
reactions are defined by her as reactions that are inert to functional groups within biological 
systems. The functional groups must, however, exhibit a specific reactivity with each other 
under cell- and organism friendly conditions. The size of the reactive groups has to be 
relatively small to prevent undesired interactions with biological systems. A reaction that 
already occurs in living organisms cannot be, by definition, a bioorthogonal reaction. Finally, 
reaction kinetics have to be reasonably high, reactants and products have to be stable in water, 






 Click reactions are especially suitable as linking chemistries. SHARPLESS et al. defined 
click chemistry as reactions that must be high yielding, have easily accessible starting 
materials, generate no- or non-toxic side-products, have a high thermodynamic driving force, 
and must be performable in a benevolent solvent such as water.[125] Figure 4 shows an 
overview on the most prominent examples of click chemistry. 
 
 
Figure 4. Overview on the different click chemistries, their properties, functional groups, and reaction kinetics. 
Reprinted from [126], copyright from The Royal Society of Chemistry.[126] 
 
From the available click type chemistries only a few are considered completely bioorthogonal, 
however, for some applications the biorthogonality does not play the most important role as in 
the case of production of nanoparticles and nanogels for the encapsulation of hydrophobic 
drugs. For the encapsulation of proteins or even living cells it is far more important to have 
completely bioorthogonal nanogel formation reactions. As in this work the inverse 
nanoprecipitation of pre-functionalized polymers is used for the formation of nanogels, the 






high conversion, without producing toxic side products and be bioorthogonal. Therefore, 
different chemistries have been explored for the purpose of the gelation of polymers.  
The Huisgen 1,3-dipolar cycloaddition between azides and alkynes that forms a triazole ring 
is one very prominent example for a predecessor of click reactions.[127] Slow reaction kinetics, 
however, limited the biomedical applicability of this reaction until the copper-catalyzed azide-
alkyne cycloaddition (CuAAC) was discovered by SHARPLESS and MELDAL, independently. 
The catalyzed version proceeds even at room temperature.[128,129] Although azides and alkynes 
are functional groups that are non-existent and inert in living organisms, CuAAC only 
partially meets the requirements for bioorthogonality.[125,130] This is due to the harming effects 
of copper ions that can bind or damage sensitive biomolecules, such as proteins.[131] 
Furthermore, copper contaminations may induce oligonucleotide[132] and polysaccharide 
degradation[133], which is the main reason for cytotoxicity coming from DNA damage. Still, 
CuAAC has been used for bioconjugation, polymer and dendrimer synthesis[134] as well as for 
the encapsulation of cells[135] into hydrogels. CuAAC is a useful tool for many applications 
that do not require full biocompatibility and allow for the removal of trace amounts of copper 
ions. However, for applications in which copper cannot be fully eliminated from the product, 
it is not a suitable crosslinking chemistry. This has led to the development of copper free 
alternatives, such as the strain promoted azide-alkyne cycloaddition (SPAAC). 
KREBS and co-workers discovered in 1961 that the cycloaddition between phenylazide 
and cyclooctyne proceeds with a very high reaction rate even at room temperature.[136] The 
enhanced reaction rates are due to ring-strain relief upon reaction of alkynes that are part of an 
eight-membered ring system with organic azides. The activation barrier for the reaction is 
significantly reduced, therefore the reaction proceeds very fast even without the addition of a 
catalyst. BERTOZZI and co-worker screened different cyclooctyne derivatives, used in SPAAC 
chemistry, regarding their reactivity.[137] The fast reaction rates even allowed for fluorescent 
labeling of cell membranes in vitro and in vivo.[138,139] 
The broad application of SPAAC in biomedical applications, however, is limited by 
long and low yielding routes for the preparation of the cyclooctyne derivatives. The synthesis 
of DIFO, a fluorinated cyclooctyne derivative, for example, requires eight consecutive 
steps.[133] Other more elaborate derivatives, such as bicyclo[6.1.0]non-4-yne (BCN) still 
require at least four steps to obtain a precursor for polymer conjugation.[140] Cross-reactivity 
of these strained cyclooctynes with free thiols has been observed,[141] thus limiting 
bioorthogonality of this reaction due to the presence of free thiols in many proteins and on 






is considerably faster than the side reaction of free thiols with cyclooctynes, thus allowing the 
encapsulation of cells without many problems.[143,144] As of today, upscaling is still very 
limited and thus hinders the application of SPAAC for problems where a large amount of 
material is needed. 
In terms of scalability Thio-Michael addition reactions outperform SPAAC. The 
synthetic precursors are readily accessible or inexpensive. Hereby, a nucleophilic free thiol is 
connected to a Michael-acceptor, e.g. acrylates, vinylsulfone, and maleimide. All of these 
groups can be introduced to a polymer backbone in a straightforward fashion. The reaction 
can be conducted in water, under mild conditions, such as room temperature and under 
physiological pH values, which makes it well optimal for gelation reactions for protein and 
cell encapsulation. However, the main drawback is the cross-reactivity of free thiols with 
maleimides and acrylates that are present in some proteins and on cell surfaces.[142,145] 
Therefore, the reaction is not considered as bioorthogonal. However, for applications, where 
cross-reactivity can be prevented or is negligible, this crosslinking chemistry is very useful 
and easily scalable. 
 
1.6.1 Inverse Electron Demand Diels-Alder 
 
The fastest- and in terms of biorthogonality, most promising click-reaction to this day, is the 
inverse electron demand Diels-Alder (iEDDA). This reaction is based on the combination of 
tetrazines and electron rich or strained dienophiles. It was first reported by CARBONI and 
LINDSEY who observed a very fast reaction between tetrazines and unsaturated compounds 









Scheme 4. Proposed mechanism of the reaction between a tetrazine and a dienophile. Energy diagram for the 
LUMO and HOMO of a neutral, normal electron demand, and inverse electron demand Diels-Alder reaction is 
shown, EDG = electron donating group, EWG = electron withdrawing group. 
 
The reaction starts with the [4+2] Diels-Alder cycloaddition between tetrazine and a 
corresponding dienophile to form the bicyclic adduct with two nitrogen bridges. This expels 
nitrogen in an immediately occurring reverse Diels-Alder reaction.[126,147–149] The removal of 
nitrogen in this case is irreversible. SAUER and co-workers studied the reactivity of a large 
variety of different tetrazines and electron rich and poor dienophiles.[150] Reaction rates span 
about nine orders of magnitude, which mostly depends on the dienophile that is used. Internal 
olefins react only slowly with tetrazines, which is an advantage, preventing the side reaction 






fastest rate constant so far of about 3300000 M-1s-1 for a conformationally strained trans-
cyclooctene.[151]Cis-cyclooctene, however, was reported to react much slower in a comparable 
setting, with a rate constant of 0.03 M-1s-1. Due to fact, that the alkenes of the cell membranes 
are not presented on the outside of the cells, side reactions are further suppressed. IEDDA has 
been used as a bioorthogonal linking strategy for fluorescent labeling of antibodies,[152] DNA-
tagging,[153] and cell labeling.[154] Due to the fast reaction rates iEDDA is considered more 
bioorthogonal than SPAAC, as possible side reactions with biological systems are slower.[99] 
There is a big variety of synthetically accessible tetrazine[155] derivatives and dienophiles. 
They offer different reactivities and synthetic accessibility, as well as stability in water.[155] 
Depending on the application, and the reaction rates needed, suitable combinations of 
tetrazine and dienophile can be chosen. Due to the easy accessibility of the precursors, this 
method can be used for the upscaling of applications such as the formation of nanogels for the 
encapsulation of therapeutic proteins. 
 As argued in the sections of this introduction, the design of nanocarriers and their 
properties remains challenging. The choice and combination of scaffold materials, as well as 
production method and linking chemistry plays a critical role for the viability and 
applicability of nanocarriers. For the encapsulation of therapeutic proteins, the use of the mild 
and surfactant-free inverse nanoprecipitation, together with the fast, scalable, and 
bioorthogonal iEDDA crosslinking chemistry would provide optimal conditions and 
properties. Therefore, in this thesis, the design, synthesis, and properties of a hydrophilic, pH-
degradable nanogel, based on the biocompatible and functionalizable dPG, that fulfils most of 
the desired criteria described by the LADMET concept, was studied. 
 





2. Scientific Goals 
 
Biotherapeutics, such as antibodies and therapeutic proteins gain ever more importance in 
modern medicine. The specificity of these protein drugs is superior to small molecules, which 
means less side effects and an improved treatment effect. However, most proteins cannot be 
orally administered, as the very low pH-value in the stomach denatures their structure. 
Furthermore, uptake in the small intestine is also not efficient for most of the biotherapeutics. 
If systemic treatment is needed, in most cases, the intravenous administration route is the only 
option to deliver protein drugs to the body. Yet, within the blood stream, proteins are 
especially sensitive to the body´s detoxification mechanisms. Small proteins with molecular 
weights below the renal excretion limit of around 45 kDa are easily eliminated from the body 
in a short period of time. Furthermore, blood proteins can bind to administered 
biotherapeutics and thus mark them for elimination by mononuclear phagocyte system (MPS), 
which is a part of the innate immune system. 
The gold standard to counteract the aforementioned problems is the covalent 
modification of the proteins with biocompatible polyethylene glycol (PEG). This PEGylation 
leads to increased molecular weights and thus, longer circulation times, as well as somewhat 
reduced blood protein binding and reduced MPS clearance. However, PEG modification can 
lead to a reduced activity of the proteins and has recently been found to induce an immune 
response in some patients.  
Alternative approaches are thus needed which also improve blood circulation times, 
and immune evasion, while not reducing the activity of the protein or provoke an immune 
response. A promising alternative for the covalent modification with PEG is the physical 
encapsulation within hydrophilic nanogels. These water-swollen polymer networks (10 -1000 
nm) provide room for proteins and keep them physically intact and shielded from blood 
proteins or antibodies. The total loaded nanogel is well above the renal excretion limit and 
thus provide prolonged circulation times. Nanogels can be produced in a size range that 
provide enhanced uptake into tumorous tissue through the enhanced permeation and retention 
(EPR) effect. Through the incorporation of environmentally responsive groups, the gels can 
be designed as smart carriers that degrade upon stimuli such as acidic- or reductive 
environments. This can be used as a way of triggered protein release at the site of action.  
As a preparation method that provides mild and surfactant free conditions, the inverse 






prevent loss of protein function and assure high encapsulation efficiencies due to the in-situ 
encapsulation during gel formation.  
 As a crosslinking chemistry, inverse-electron demand Diels-Alder (iEDDA) based on 
tetrazines and dienophiles, shows the most promising kinetics, biocompatibility, accessibility 
of the precursors, as well as biorthogonality compared to other click type reactions such as 
strain promoted azide alkyne cycloaddition reactions (SPAAC). 
Thus, the aim of this work is to design a macromonomer platform based on the 
polymer dendritic polyglycerol (dPG) which is easily functionalizable, biocompatible, and 
highly hydrophilic. This polymer shall be functionalized with a selection of different 
dienophiles and tetrazine, in order to obtain for the first time a library of substances, which is 
easily accessible and/or reactive during an inverse nanoprecipitation to form nanogels. The 
macromonomers will be studied regarding their properties in context of nano gelation, 
including gelation times, aggregation, and stability in aqueous solution. Influencing 
parameters, such as solvent to non-solvent ratio, quenching times, and macromonomer 
concentration will be screened to find optimal conditions for nanogel formation in the desired 
size range of 20 to 200 nm. The most promising candidates in terms of reactivity, stability in 
aqueous solution, and accessibility will then be used for the co-precipitation of a model 
protein, such as myoglobin.  
Based on the screening results, environmentally degradable dPG-macromonomers will 
be designed. pH-degradability of the nanogels should be achieved by the incorporation of 
acetal linking groups in-between the polymer and the reactive dienophile functional groups. 
Different acetal linkers will be used to obtain nanogels that can be cleaved at different pH-
values. The most promising dienophile from the screening will be used as the dienophile and 
compared to the commercially available bicyclo[6.1.0]non-4-yne (BCN). The obtained 
macromonomers will be tested regarding their cytocompatibility and then used in the 
preparation of pH-degradable nanogels using inverse nanoprecipitation. Degradability of the 
gels will be tested by subjection to different pH values. The therapeutic protein Asparaginase 











3.1 Systematic Screening of Different Polyglycerin-Based Dienophile 
Macromonomers for Efficient Nanogel Formation through IEDDA Inverse 
Nanoprecipitation 
 




Alternatives for strain-promoted azide–alkyne cycloaddition (SPAAC) chemistries are needed 
because of the employment of expensive and not easily scalable precursors such as 
bicyclo[6.1.0]non-4-yne (BCN). Inverse electron demand Diels Alder (iEDDA)-based click 
chemistries, using dienophiles and tetrazines, offer a more bioorthogonal and faster toolbox 
especially in the biomedical field. Here, the straightforward synthesis of dPG-dienophiles and 
dPG-methyl tetrazine (dPG-metTet) as macromonomers for a fast, stable, and scalable 
nanogel formation by inverse nanoprecipitation is reported. Nanogel size influencing 
parameters are screened such as macromonomer concentration and water to acetone ratio are 
screened. dPG-norbonene and dPG-cyclopropene show fast and stable nanogel formation in 
the size range of 40–200 nm and are thus used for the coprecipitation of the model protein 
myoglobin. High encapsulation efficiencies of more than 70% at a 5 wt% feed ratio are 
obtained in both cases, showing the suitability of the mild gelation chemistry for the 
encapsulation of small proteins. 
 
 
Contributions: Study design, synthesis of precursors and parts of macromonomers, synthesis 
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nature and small and unspecific interac-
tions with blood proteins.[10–14] The size 
of a nanogel is typically above the renal 
threshold, yielding increased circulation 
times for the encapsulated proteins. Fur-
thermore, nanogels only physically entrap 
the protein instead of forming covalent 
bonds such as in the case of PEGylation, 
preventing any detrimental influence of 
covalent modifications.[3,6]
A variety of different methods are avail-
able for the preparation of nanogels. The 
most common preparation methods are 
the mini- and microemulsion polym-
erizations of monomers or macromono-
mers.[15–23] These methods utilize droplets 
of reactive monomers in the desired size 
range which are obtained by high energy 
input from ultrasonication in miniemul-
sion and large surfactant amounts in 
microemulsions. Subsequent crosslinking 
of the monomers in those templated droplets led to a disper-
sion of polymer beads in the nanometer to micrometer range. 
However, the use of ultrasonication and surfactants has the 
downside of not providing mild conditions for the in situ encap-
sulation of proteins and poses problems with purification.[23–25]
A very useful method for the preparation of hydrophobic 
nanoparticles is the nanoprecipitation method, which is based 
on the insolubility of certain growing polymers in a corre-
sponding non-solvent.[26] For example, polystyrene (PS),[27] poly-
lactic acid, and copolymers of polylactic and glycolic acid (PLA/
PLA-co-PGA)[26,28] nanoparticles have been prepared in such a 
fashion. These polymers can be used for the encapsulation of 
hydrophobic drugs. Our group reported the use of an inverse 
nanoprecipitation method with hydrophilic macromonomers 
based on dendritic polyglycerol (dPG).[7] Due to the reversal 
of polarity in this method, a surfactant-free, mild, and easy 
to purify way of producing nanogels is offered. Proteins were 
encapsulated with high efficiency and retained their function-
ality upon release.
During inverse nanoprecipitation, the macromonomers 
form nanoaggregates due to the diffusion of the solvent into 
the non-solvent. These aggregates then must be crosslinked in 
order to obtain a stable polymer network that does not break 
up upon dilution with water. The type of crosslinking chem-
istry has thus a very big impact on the gel formation process. 
Click-type reactions are especially suitable for this application. 
They are fast and usually proceed in a quantitative fashion.[29] 
Alternatives for strain-promoted azide–alkyne cycloaddition (SPAAC) chem-
istries are needed because of the employment of expensive and not easily 
scalable precursors such as bicyclo[6.1.0]non-4-yne (BCN). Inverse electron 
demand Diels Alder (iEDDA)-based click chemistries, using dienophiles and 
tetrazines, offer a more bioorthogonal and faster toolbox especially in the 
biomedical field. Here, the straightforward synthesis of dPG-dienophiles and 
dPG-methyl tetrazine (dPG-metTet) as macromonomers for a fast, stable, 
and scalable nanogel formation by inverse nanoprecipitation is reported. 
Nanogel size influencing parameters are screened such as macromonomer 
concentration and water to acetone ratio are screened. dPG-norbonene and 
dPG-cyclopropene show fast and stable nanogel formation in the size range 
of 40–200 nm and are thus used for the coprecipitation of the model protein 
myoglobin. High encapsulation efficiencies of more than 70% at a 5 wt% feed 
ratio are obtained in both cases, showing the suitability of the mild gelation 
chemistry for the encapsulation of small proteins.
Therapeutic protein drugs are on the rise in the treatment 
of various diseases, due to their increased specificity com-
pared to small molecules. However, they suffer the drawback 
of increased immune recognition and undergo renal clear-
ance if their size is below the renal threshold of 45 kDa or a 
hydrodynamic diameter of about 5.5 nm.[1,2] In order to pre-
vent the rapid clearance, the proteins are usually PEGylated 
to increase their total molecular weight and reduce immune 
recognition.[3–6] However, PEG seems to be able to induce an 
immune response, as well as hypersensitivity reactions in some 
patients.[6]
Moreover, to prevent the immune recognition, therapeutic 
proteins can be masked by non-covalent encapsulation in nano-
carriers such as nanogels.[7–10]
These nanogels are commonly highly water-swollen polymer 
networks in the size range of 10–1000 nm that offer a stealth 
effect to any protein cargo inside, due to their hydrophilic 
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Copper-catalyzed Huisgen 2 + 3 cycloaddition, for example, is 
based on the reaction of organic azides with terminal organic 
alkynes and has been used for the preparation of nanoparti-
cles and nanogels.[29] The reactive groups are easily obtained, 
although the need of copper as a catalyst is a major drawback. 
Copper ions are usually hard to remove and can bind to some 
proteins and therefore subject cells to oxidative stress due to 
the production of reactive oxygen species, diminishing the 
biocompatibility of nanogels produced in such a manner.[30] 
Copper-free alternatives exist, where the terminal alkyne is 
replaced by a strained version, usually embedded in an eight-
membered ring system.[31] These highly strained systems allow 
for the complete elimination of copper, because the ring-strain 
release upon reaction with the azide provides the driving force 
for the coupling reaction. Yet, some major drawbacks of these 
strain-promoted azide–alkyne cycloaddition (SPAAC) reactions 
are the high price for the precursor molecules, as well as the 
tedious and low-yielding synthetic protocols, especially for 
BCN.
Another common crosslinking method, the thiol-ene reac-
tion, is based on free thiols reacting with olefin derivatives. 
This method has the advantage of easily accessible macromon-
omers, which makes the process scalable and comparatively 
inexpensive. However, it is incompatible with proteins that con-
tain free thiols.[32]
We have previously reported on nanogels, which are based 
on a hydrophilic, biocompatible, and easy to functionalize dPG-
backbone.[33,34] A lot of the aforementioned different linking 
strategies have been used, such as CuAAC,[7] thiol-ene,[35,36] and 
the SPAAC reaction.[37]
Due to the drawbacks of some of these methods, the need 
for newer generations of click reactions arose. One of the most 
recent advances in “click chemistry” was the development 
of inverse electron demand Diels-Alder (iEDDA) reactions 
based on tetrazine derivatives and different dienophiles.[38–41] 
Depending on the dienophiles and tetrazines used, the reac-
tion kinetics can be orders of magnitude faster than the cor-
responding SPAAC alternatives.[41]
IEDDA has been used as a bioorthogonal linking strategy for 
fluorescent labeling of antibodies,[42] DNA-tagging,[43] and even 
cell labeling.[44] Due to the fast reaction rates, iEDDA is con-
sidered more bioorthogonal than SPAAC, as any possible side 
reactions with biological systems are much slower.[45] There is 
a big variety of synthetically accessible tetrazine[46] derivatives 
and dienophiles. They all offer different reactivities and syn-
thetic accessibility as well as stability in aqueous solutions.[46] 
Depending on the application, one can choose the most suit-
able combination of tetrazine and dienophile.
We hypothesize that these characteristics of iEDDA reactions 
are thus optimal for the substitution of SPAAC in the forma-
tion of nanogels by inverse nanoprecipitation.
We present the synthesis of new dPG-based macromono-
mers functionalized with methyl-tetrazine and different dieno-
philes such as the well-known norbonene, methyl-cyclopro-
pene, and dihydropyran (DHP). The macromonomers are char-
acterized by NMR and DLS and tested regarding their ability 
to form macrogels, as well as stable nanogels during inverse 
nanoprecipitation in acetone. The most promising macromon-
omers dPG-norbonene and dPG-cyclopropene are used for the 
in situ coprecipitation of the small protein myoglobin (17 kDa) 
and show very good encapsulation efficiencies up to 93%. The 
fast and efficient synthetic route to dPG-norbonene and dPG-
metTet, as well as the stable and scalable nanogels that are 
obtained from them, while avoiding the drawbacks of other 
crosslinking strategies makes this a possible new platform for 
the bioorthogonal encapsulation of therapeutic proteins.
The success of a nanocarrier depends on its key physical 
properties, such as the nature of the material that it is made 
of (e.g., functional groups), hydrophilicity/hydrophobicity bal-
ance, and the size, as well as the synthetic accessibility of the 
respective crosslinkers. We chose, for the purpose of a high 
biocompatibility and ease of functionalization, the already 
well known dPG.[33,34,47,48] Due to its large amount of terminal 
hydroxyl groups, it is highly hydrophilic and easy to function-
alize without losing its hydrophilicity upon a low degree of 
functionalization. The polymer itself can be synthesized in kilo-
gram scale which makes it a very suitable candidate as a mac-
romonomer for nanogel synthesis.
We chose the inverse nanoprecipitation method for the for-
mation of the nanogel network as no surfactant is needed and 
thus a mild encapsulation of proteins becomes possible. In 
order to achieve a stable gel in a fast way, the iEDDA chemistry 
was chosen as a gel crosslinking strategy due to its biorthogo-
nality and high reaction rates. However, the stability of the reac-
tive groups to reaction conditions, as well as storage conditions 
is also very important for potential applications.
For our work, we therefore selected a water stable tetrazine 
derivative, which still has a moderate reactivity toward dieno-
philes and can be easily attached to the dPG-core. 4-(6-Methyl-
1,2,4,5-tetrazin-3-yl)benzoic acid was thus chosen, which can be 
attached via simple amide bond formation to a dPG-amine core. 
As the counterpart, four different dienophiles were chosen, in 
order to compare their reactivity during gel formation and the 
stability of the final nanogels in terms of aggregation. As can 
be seen in Scheme 1, we obtained four different dPG-dieno-
philes with approximately the same degree of functionalization 
starting from a 6 kDa dPG core. The different dPG-macromon-
omers are depicted as the corresponding colored spheres.
The synthetic overview for the precursor molecules (1–5) can 
be found in Scheme S1, Supporting Information.
One great advantage of using iEDDA chemistry compared 
to strained alkyne–azide cycloaddition is the accessibility of the 
reactive tetrazines and dienophiles. The tetrazine precursor 
4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzoic acid was obtained 
according to a one-pot reaction reported in literature in a 
moderate yield of 40% but can be used for functionalization 
with any kind of amine and has a good stability in water and 
buffer.[46] The different dienophiles were synthesized as the 
reactive carbonate derivatives. In this form, they can be reacted 
with any kind of amine, yielding the corresponding carbamate-
linked dienophiles. In contrast, the synthesis of BCN is quite 
lengthy, with five steps and an overall yield of only 27%. In the 
series of dienophiles reported here, BCN is known to be one 
of the most reactive dienophiles in tetrazine click-reactions.[49] 
The next one in line in terms of reactivity is the cyclopropene 
derivative, which we obtained in four steps with a low overall 
yield of 19%. We chose the structural motive of bicyclo[2.2.1]
hept-5-ene-2-carbaldehyde as a precursor as it is commercially 
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available at a low price and was easily transformed in two steps 
with a good overall yield of 84% to the reactive carbonate form 
bicyclo[2.2.1]hept-5-en-2-ylmethyl (4-nitrophenyl) carbonate. 
Thus, norbonene was the most promising and well-known 
dienophile candidate in terms of potential upscaling and com-
mercial use, even though it presents a relatively moderate reac-
tivity.[50] The last dienophile we tested, was based on a common 
protecting group for alcohols. The (3,4-dihydro-2H-pyran-2-yl)
methanol is commercially available for a relatively low price 
and is structurally related to 3,4-dihydropyrane (DHP). The 
commercial precursor was transformed to the activated DHP 
carbonate (3,4-dihydro-2H-pyran-2-yl)methyl (4-nitrophenyl) 
carbonate in one step, with a yield of 79%. This structural motif 
is known as a dienophile in literature; although, the reaction 
rates are considerably lower compared to the other structural 
motives used in this work.[51]
With the reactive dienophiles and tetrazine in hand, the func-
tionalization of the polymer core, dPG-amine, was performed 
in a straightforward fashion using the same procedure for every 
dienophile (Scheme 1). This provided us with a toolbox of mac-
romonomers for the formation of nanogels. The macromono-
mers were characterized by NMR, IR, and DLS, as can be seen 
in the Supporting Information.
In a first screening, we used the macromonomers in the for-
mation of macroscopic hydrogels to determine the reactivity of 
each type of dienophile. This was investigated by measuring 
the time required for the gelation of a mixture of dPG-metTet 
with the respective dPG-dienophile. As can be seen in Figure 1, 
the dPG-cyclopropene was the macromonomer with the fastest 
gelation time. It was followed in reactivity by dPG-norbonene. 
dPG-BCN and dPG-DHP did not show any macrogel formation 
even after 30 min.
Only an increased viscosity was observed for dPG-BCN. 
As BCN was supposed to have the highest reaction rates, we 
expected it to have the fastest macrogel formation. We hypothe-
sized that, due to the fast reaction, the dPG-BCN was quenched 
almost instantaneously before a network formation could 
happen. The lower reactivity of cyclopropene and norbonene 
led to diffusion of macromonomers within the network and 
thus to a stable gel formation. As expected, the cyclopropene 
derivative reacted faster than the norbonene derivative. How-
ever, both showed macrogel formation in a reliable manner. 
Only dPG-DHP was too unreactive and did not yield even an 
increased viscosity of the macromonomer mix.
Subsequently, we performed the synthesis of nanogels via 
inverse nanoprecipitation. The process works by fast injection 
of a dilute macromonomer solution into the corresponding 
non-solvent. In our case, the non-solvent for dPG-based 
Macromol. Rapid Commun. 2019, 1900510
Scheme 1. Synthetic overview for the different macromonomers dPG-BCN, dPG-norbonene, dPG-cyclopropene, dPG-DHP, and dPG-metTet. The fol-
lowing conditions were used: a) MsCl, NEt3, DMF, rt, overnight; b) NaN3, 60 °C, 3 d; c) PPh3, water/THF, rt, 3 d; d) 1, NEt3, DMF, rt, overnight; e) 2, 
NEt3, DMF, rt, overnight; f) 3, NEt3, DMF, rt, overnight; g) 4, NEt3, DMF, rt, overnight; and h) 5, HATU, DIPEA, DMF, rt, overnight. Number of reactive 
groups not representative; just for clearness.
Figure 1. Macrogelation for the dPG-dienophiles MM2 and MM3, n = 
3. A) Gelation times of MM2 and MM3 measured in triplicate. Control 
depicts the measurement setup with a small glass vial at an angle of 
45° and MM5 without crosslinker. B) Macrogel of MM2 after 30 min. 
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polymers was acetone. The schematic overview on the inverse 
nanoprecipitation process can be seen in Scheme 2.
A lot of parameters can influence the outcome of the nano-
precipitation method such as macromonomer concentration, 
solvent/non-solvent ratio, stirring speed, temperature, mac-
romonomer ratio, and reaction time. Usually, the size distri-
bution and polydispersity are influenced by the parameters 
described above. For biomedical applications, nanogel sizes 
in the range of 20–200 nm are desirable.[52,53] We investigated 
most of these parameters for the most promising dienophile 
dPG-norbonene. The gels were produced by separately dis-
solving the respective macromonomers in water and then 
mixing dPG-dienophile with dPG-metTet, just prior to injection 
into acetone. Depending on the experiment, different amounts 
of the stock solutions were employed. The macromonomer 
solutions were cooled to 4 °C in order to prevent premature 
crosslinking.
First, the influence of the macromonomer concentration in 
water on the nanogel formation was studied. As can be seen 
in Table 1, the concentration was changed between 0.5 and 
5 mg mL−1.
The macromonomer concentration apparently did not have a 
relevant influence on the size or the polydispersity of the nano-
gels. However, for a concentration of 1 mg mL−1, we observed a 
disturbed gel formation, that led to very large gels with a high 
polydispersity. As the macromonomer concentration in water 
directly correlates with the scalability of the process, we chose 
the highest concentration of 5 mg mL−1 for further studies.
In order to prevent subsequent crosslinking of already 
formed nanogels, an excess of one of the macromonomers was 
used. The ratio of reactive groups was set to 1:1.5. dPG-metTet 
exhibits a pink color, which can be used as an indicator of the 
status of the reaction. For this reason, dPG-metTet was used in 
shortfall to the other macromonomer to observe completion 
Macromol. Rapid Commun. 2019, 1900510
Table 1. Concentration dependence of dPG-norbonene/dPG-metTet-NGs.
Entry Macromonomer V(H2O): V(acetone) Tq, chem [min] Tq, water [min] Z-average [nm] PDI
Ratio (A:B) C [mg mL−1]
1 1:1.5 5 1:40 5 30 163 ± 13 0.02 ± 0.01
2 1:1.5 2.5 1:40 5 30 209 ± 21 0.03 ± 0.02
3 1:1.5 1 1:40 5 30 1528 ± 801 0.6 ± 0.1
4 1:1.5 0.5 1:40 5 30 190 ± 20 0.03 ± 0.02
A, dPG-metTet; B, dPG-norbonene; size values correspond to the mean of three individual gels.
Scheme 2. Overview on nanogel formation by inverse nanoprecipitation in acetone with dPG-norbonene as an example. Linking points and structure 


































































































































© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1900510 (5 of 11)
www.advancedsciencenews.com www.mrc-journal.de
of the reaction. Additionally, a chemical quencher (2-(viny-
loxy)ethan-1-ol) was used in order to deactivate the remaining 
methyl-tetrazine groups. The influence of the time, after which 
the chemical quencher was added, on the nanogel formation is 
reported in Table S2 and Figure S2, Supporting Information.
No clear trend could be seen, as the size was in the same 
range for all different time points and the PDI stayed below 0.1. 
Apparently, the reaction rates were so fast for the crosslinking 
reaction that the chemical quencher did not have an influence 
on the nanogel formation, whatsoever. Aggregation of already 
formed nanogels was also not an issue, as even without the 
addition of a chemical quencher, the gels stayed stable and 
maintained their size (Table S2, Supporting Information, 
entry 1). In order to assure that no crosslinking would happen, 
we chose to add the chemical quencher anyway and used 
10 min as the delay time for its addition.
Due to the stability of the system, which gave in most of the 
cases, reproducibly nanogels in the size range of 180–200 nm, 
we wanted to see if it is possible to influence the particle size 
while still maintaining a good PDI. As the crosslinking seemed 
to be almost complete after 10 min, we tried to physically quench 
the nanogel formation after defined time spans. Water was added 
to decrease the local macromonomer concentration and to break 
up any preformed aggregates that did not crosslink yet. As can 
be seen in Table 2 and Figure 2, the nanogel size was not really 
affected after roughly 30 min. If the gels were not quenched at 
all, then complete precipitation occurred overnight (Table 2, entry 
1). For quenching times of 60 and 30 min, there was no differ-
ence in nanogel size. However, quenching after 10 and 5 min 
showed a significant reduction in nanogel size while still main-
taining a low PDI value of less than 0.1. Quenching at 1 and 
2.5 min nanogel formation was severely hampered. Only small 
aggregates of around 40 nm were observed in DLS (vol%) for a 
reaction time of 2.5 min, whereas no reliable measurement could 
be obtained for a reaction time of 1 min. This trend of smaller 
particles after short reaction times can be explained with the 
dissolution of non-crosslinked aggregates. Figure 3 shows the 
overall trend between water quenching time and nanogel size.
Due to the fast reaction rates the size distribution quickly 
reached saturation. Therefore, there is only a small time 
window to influence the size of the nanogels towards smaller 
values.
Another way to control the size of nanogels is to change the 
ratio of solvent to non-solvent. The right ratio depends on the 
actual solubility of the macromonomers in each solvent. For 
extremely high ratios of solvent to non-solvent, there will not 
be nanogel formation anymore as the macromonomers do 
not aggregate in very low amounts of the non-solvent. As the 
ratio decreases, the macromonomers can aggregate due to their 
decreasing solubility in the mixture of solvent and non-solvent.
The effect of several ratios of solvent and non-solvent, 
ranging from 1:20 to 1:200, are reported in Table 3.
For low ratios such as 1:200 to 1:80, the nanogel formation 
was strongly disturbed, leading to precipitation. Meaningful 
size values could not be determined, because the measurement 
quality was not achieved in DLS. Ratios of 1:60 to 1:20, how-
ever, were suitable for nanogel formation, with higher ratios 
leading to smaller nanogels. The polydispersity of the gels was 
in all cases below 0.1, which suggested a stable gel formation 
for such high ratios of solvent to non-solvent. This was a very 
promising result, as the main drawback of the inverse nano-
precipitation method is that very high amounts of non-solvent 
are needed for the preparation of relatively small amounts of 
Macromol. Rapid Commun. 2019, 1900510
Table 2. Dependance of water quenching time on dPG-norbonene/dPG-metTet-NGs.
Entry Macromonomer Tq, water [min] Z-average [nm] PDI
Ratio (A:B) C [mg mL−1]
1 1:1.5 5 On nd nd
2 1:1.5 5 60 194 ± 6 0.07 ± 0.02
3 1:1.5 5 30 188 ± 9 0.07 ± 0.02
4 1:1.5 5 10 136 ± 5 0.07 ± 0.01
5 1:1.5 5 5 121 ± 4 0.06 ± 0.02
6 1:1.5 5 2.5 41 ± 4 0.40 ± 0.03
7 1:1.5 5 1 nd nd
A, dPG-metTet; B, dPG-norbonene; nd, measurement quality criteria not achieved due to very high polydispersity; V(H2O):V(acetone) = 1:40; Tq, chem = 10 min; on = 
overnight.


































































































































© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1900510 (6 of 11)
www.advancedsciencenews.com www.mrc-journal.de
nanogels, usually a ratio of 1:200. Obtaining stable and almost 
monodisperse nanogels with a relatively high ratio of 1:20 
means that the nanogel formation is scalable. For all batches, 
we used 5 mg of macromonomers, as higher amounts make it 
usually time consuming to remove acetone. To obtain relevant 
amounts of nanogels, we wanted to confirm if the production 
process is scalable to ten times the amount that is usually taken 
for a gel batch. Table 4 shows the obtained nanogels for 50 mg 
batches.
Gels in the size range of 100–120 nm were obtained with 
PDI values below 0.1. The three gels were combined to yield 
a single dispersion of nanogel in water, with an average size 
distribution between the three gels and a PDI value of 0.1. This 
showed that several batches could be combined without a big 
increase in polydispersity. The scalability of a single batch and 
the possible combination of several batches into one batch thus 
holds the possibility to produce these nanogels in gram scale.
The stirring speed can also influence the nanogel forma-
tion. Table S3 and Figure S3, Supporting Information show the 
effect of different stirring speeds on the size and polydisper-
sity of the nanogels. The stirring speed had no relevant influ-
ence on the size and PDI of the nanogels, although the same 
volume of non-solvent was used for each stirring speed. Thus, 
the highest stirring speeds were used for all the experiments.
The other combinations of macromonomers were then 
studied. Starting with the lowest reactivity, dPG-DHP was 
Macromol. Rapid Commun. 2019, 1900510
Table 3. dPG-norbonene/dPG-metTet-NGs; water:acetone ratios.
Entry Macromonomer V(H2O): V(acetone) Z-average [nm] PDI
Ratio (A:B) C [mg mL−1]
1 1:1.5 5 1:200 nd nd
2 1:1.5 5 1:150 nd nd
3 1:1.5 5 1:100 nd nd
4 1:1.5 5 1:80 nd nd
5 1:1.5 5 1:60 233 ± 10 0.06 ± 0.01
6 1:1.5 5 1:40 165 ± 7 0.06 ± 0.01
7 1:1.5 5 1:20 110 ± 4 0.09 ± 0.01
A, dPG-metTet; B, dPG-norbonene; nd, measurement quality criteria not achieved due to very high polydispersity; Tq, chem = 10 min and Tq, water = 30 min.
Figure 3. Overview on nanogel formation behavior, synthetic accessibility, and reactivity of the different macromonomers. DLS measurement of an 
exemplary gel is shown for each macromonomer, directly after synthesis and purification (black line) and after 4 to 5 months (red line). A) dPG-
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tested regarding its ability to form nanogels. As already shown, 
the macrogel experiments did not yield any gel after extended 
periods of time for dPG-DHP. Even after a reaction time of 
18 h, only the non-crosslinked macromonomers could be 
seen by DLS (Figure 3). This showed that the reactivity of the 
DHP moiety was far too low for a nanogel formation. Thus, 
we decided to not investigate the dPG-DHP macromonomer 
further as useful time spans for gel formation could not be 
achieved.
dPG-BCN showed a delayed and incomplete gelation during 
macrogel formation. As can be seen in Tables S4 and S5, Sup-
porting Information, the optimal conditions for nanogel forma-
tion, which were observed for dPG-norbonene, were also tested 
for dPG-BCN. The nanogel formation leads almost in all cases 
to big aggregates with high polydispersities, which are also not 
dependent on the preparation conditions. No reproducibility 
could be observed under the tested conditions, as size values 
scattered from 100 to 2000 nm, with PDI values between 0.2 
and 0.8. We assumed that the high reactivity of BCN led to pre-
mature crosslinking and further crosslinking of the nanoaggre-
gates that formed during the inverse nanoprecipitation. This 
resulted in a very fast growth of bigger and bigger aggregates. 
This might explain the big and polydisperse gels we observed 
with this macromonomer.
The last macromonomer that was tested was dPG-cyclopro-
pene. The cyclopropene moiety is rather small compared to the 
alternatives presented in this work and in literature. In general, 
it does not have as big of an influence on hydrophilicity as dien-
ophiles, such as BCN. Moreover, the reactivity toward tetrazine 
derivatives is also reported to be moderately high.[54] However, 
the synthesis reported in literature is quite lengthy. Hence, it 
could be an alternative to norbonene, in cases where very small 
and less hydrophobic crosslinkers are needed, despite the draw-
back of low scalability. As for the other macromonomers, dif-
ferent conditions were tested, which are summarized in Table 
S6, Supporting Information. dPG-cyclopropene, as well as dPG-
norbonene, showed stable nanogel formation in the size range 
of 70–120 nm. This macromonomer also yielded nanogels with 
very low polydispersity indices of below 0.1.
Zeta potential measurements (Figure S4, Supporting Infor-
mation) showed that all gels had a close to neutral surface 
charge. dPG-norbonene and dPG-cyclopropene nanogels were 
slightly positively charged and dPG-BCN nanogels slightly neg-
atively charged.
A summary of the nanogel formation process for the dif-
ferent macromonomers is described in Figure 3 and the corre-
sponding NTA measurements can be found in Figure S5, Sup-
porting Information.
Of all the dienophiles, dPG-norbonene and dPG-cyclopro-
pene showed reliably nanogel formation in the biologically rel-
evant size range of below 100–200 nm. The most influencing 
parameters on nanogel size and polydispersity were water to 
acetone ratio and the water quenching time Tq,water. dPG-nor-
bonene, however, is by far the most promising candidate for the 
easy upscaling and robust application, due to the straightfor-
ward synthesis of the precursors and the stable and monodis-
perse nanogels which can be obtained.
Due to their stable and reproducible nanogel formation, 
dPG-norbonene and dPG-cyclopropene were used in copre-
cipitation experiments with the protein myoglobin. During the 
mild coprecipitation, the protein was first physically encapsu-
lated by the formation of nanoaggregates in the acetone phase. 
This polyglycerol shell around the protein protects it from the 
organic solvent and provides, due to the many hydroxyl groups, 
an almost natural environment to it. As the aggregates of poly-
glycerol macromonomers start to crosslink, the protein stays 
physically entrapped in the growing polymer network and dif-
fusion gets ever more hindered. Due to the very mild reaction 
conditions of iEDDA and the absence of surfactants, high tem-
perature and radicals, the sensitive protein cargo is very likely 
to be intact after nanogel formation.
Myoglobin, a small 17 kDa protein which is mostly respon-
sible for oxygen transport within muscle tissue, was used as an 
inexpensive and abundant model protein for coprecipitation. 
We tested two different myoglobin feed ratios, a higher 5 wt% 
and lower 2.5 wt% of myoglobin compared to macromonomer. 
Tables S7 and S8, Supporting Information summarize the con-
ditions we used and the nanogel sizes and polydispersity values 
that were obtained for dPG-norbonene and dPG-cyclopropene 
macromonomers, respectively.
The addition of a protein to the system changes the aggre-
gation behavior during inverse nanoprecipitation signifi-
cantly. The sizes of the nanogels at least doubled compared 
to the same conditions without protein (Figure 4A). However, 
the polydispersity indices of the formed nanogels, stayed low 
(below 0.1).
The determination of protein concentration within the gels 
was performed by a bicinchoninic acid (BCA) assay using 
bovine serum albumin (BSA) and myoglobin standard curves 
(Figures S6 and S7, Supporting Information). The total amount 
of protein was determined by multiplying the concentration 
of protein, determined in the BCA assay, by the total volume 
Macromol. Rapid Commun. 2019, 1900510
Table 4. Nanogel formation of dPG-norbonene/dPG-metTet (50 mg batch size).
Entry Macromonomer Z-average [nm] PDI
Ratio (A:B) C [mg mL−1]
1 1:1.5 5 122 ± 1 0.07 ± 0.01
2 1:1.5 5 129 ± 2 0.07 ± 0.01
3 1:1.5 5 104 ± 2 0.07 ± 0.01
Avg. 1:1.5 5 118 ± 11 0.07 ± 0.01
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of the individual gel dispersions and then divided by the feed 
amount of protein. The results can be seen in Figure 4.
Both dPG-norbonene as well as dPG-cyclopropene nano-
gels could encapsulate myoglobin with a very high encapsu-
lation efficiency of 75–93% at 5 wt% feed. The control shows 
only dPG-norbonene without dPG-metTet as crosslinker. The 
control sample was treated in the same way as the other sam-
ples, however, as no crosslinker was present, no gel formation 
was expected. Thus, no protein should have been present after 
centrifugal filtration. As confirmation, almost no protein was 
observed in the control experiments.
The results clearly showed, that the nanogels, which 
were formed through iEDDA click chemistry, especially the 
dPG-norbonene-based NGs, could efficiently encapsulate 
myoglobin.
We have shown the synthesis of different amine-reactive 
dienophiles as a toolbox for the functionalization of dPG-
amine. The activated carbonates of norbonene, BCN, cyclo-
propene, and DHP were synthesized. The corresponding 
carbamate-linked dPG-dienophiles were obtained by a stand-
ardized procedure. The macromonomers dPG-norbonene 
and dPG-cyclopropene showed a fast macrogel formation 
within 12 min and nanogels in the size range of 40–200 nm 
were obtained with excellent polydispersity indices of 0.1 and 
below. dPG-norbonene-based nanogels were reproducibly 
synthesized under a wide range of conditions and showed 
batch scalability to at least 50 mg per batch. Combination of 
different batches yielded gels that retained the low polydis-
persity of the individual batches. dPG-BCN and dPG-DHP 
showed non-reproducible or no gel formation at all, respec-
tively. In case of dPG-BCN, the reason was probably due to 
very high reaction rates and thus premature cross-linking 
and, in the case of dPG-DHP, a very low reactivity and hence, 
no crosslinking at all.
Coprecipitation of myoglobin (17 kDa) showed excel-
lent encapsulation efficiencies of up to 93% for nano-
gels made from dPG-norbonene and dPG-cyclopropene, 
respectively.
All in all, dPG-norbonene is the most promising candidate 
for nanogel formation with dPG-metTet, within the series of 
dienophile macromonomers presented in this work, in terms 
of synthetic access to the precursors, scalability, and reproduci-
bility of the system. Thus, the goal for future studies will be the 
preparation of responsive nanogels based on dPG-norbonene/
dPG-metTet for the triggered degradation and release of thera-
peutic proteins.
Macromol. Rapid Commun. 2019, 1900510
Figure 4. Influence of coprecipitation of myoglobin on nanogel size for dPG-norbonene and dPG-cyclopropene nanogels at 5 wt% myoglobin feed. 
A) left: DLS data for a dPG-norbonene-NG without (black line) and with (red line) encapsulated myoglobin; right: DLS data for dPG-cyclopropene-NG 
without (black line) and with (red line) encapsulated myoglobin. B) Encapsulation efficiency at 5 wt% feed of myoglobin in dPG-norbonene and dPG-
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Experimental Section
Materials: The solvents n-pentane, ethyl acetate, and diethyl ether 
were obtained from the technically pure solvents by distillation before 
use. DCM and acetone (HPLC grade) were used without further 
purification. Dry DCM and THF were taken from a SPS-800 type 
MBRAUN solvent drying system. Dry methanol and DMF were acquired 
from Acros and Fischer Chemical. All other chemicals and deuterated 
solvents were purchased from Sigma Aldrich, Merck, Acros, and Fisher 
Chemicals and were used as reagent grade without further purification. 
Qualitative thin layer chromatography (TLC) was performed on silica gel-
coated aluminum plates serving as stationary phase (silica gel 60 F254 
from Macherey-Nagel). The analytes were identified by irradiation of the 
TLC plates with UV light (λ = 254 nm) or by treatment with a potassium-
permanganate-based staining reagent (100 mL deionized water, 200 mg 
potassium permanganate) or anis aldehyde-based (450 mL EtOH, 
25.0 mL anis aldehyde, 25.0 mL conc. sulfuric acid, 8.0 mL acetic acid). 
Column chromatography was performed with silica gel of the company 
Macherey-Nagel (grain size 40–63 µm, 230–400 mesh) as stationary 
phase and the indicated eluent mixtures as mobile phase.
Analytical Methods: IR spectra were recorded on a JASCO FT/IR-4100 
spectrometer. The characteristic absorption bands were given in wave 
numbers. 1H NMR spectra were recorded at 300 K on Joel ECX 400 
(400 MHz) and AVANCE III (700 MHz) instruments. Chemical shifts 
δ were indicated in parts per million (ppm) relative to tetramethyl 
silane (0 ppm) and calibrated as an internal standard to the signal of 
the incompletely deuterated solvent (CDCl3: δ = 7.26 ppm, MeOD: δ = 
3.31 ppm). Coupling constants J were given in Hertz. 13C NMR spectra 
were recorded at 300 K on AVANCE III instruments (176 MHz). Chemical 
shifts δ were given in ppm relative to tetramethyl silane (0 ppm) and 
calibrated as an internal standard to the signal of the incompletely 
deuterated solvent (CDCl3: δ = 77.16 ppm, MeOD: δ = 49 ppm). 
Coupling constants J were given in Hertz. The spectra were decoupled 
from proton broadband. DLS and Zeta potential were measured on a 
Malvern zeta-sizer nano ZS 90 with He–Ne laser (λ = 532 nm) at 173° 
backscatter and automated attenuation at 25 °C. Three measurements 
were performed per sample with between 10 and 16 individual 
measurements, yielding a mean size value plus standard deviation. 
Sample concentration was kept at 1 mg mL−1. GPC was performed on 
an Agilent 1100 at 5 mg mL−1 using a pullulan standard, 0.1 m NaNO3 
solution as eluent, and a PSS Suprema column 10 µm with a flow rate of 
1 mL min−1. Signals were detected with an RI detector.
Precursors and Macromonomers: All air- and moisture-sensitive 
reactions were carried out in flasks in an inert atmosphere (argon) 
using conventional Schlenk techniques. Reagents and solvents were 
added via argon rinsed disposable syringes. Solids were added in argon 
counterflow or in solution.
The synthesis of the literature known precursors is described in the 
Supporting Information, showing the modified procedures.
Bicyclo[2.2.1]hept-5-en-2-ylmethyl (4-nitrophenyl) Carbonate (1): In 
a dried 500 mL Schlenk flask, bicyclo[2.2.1]hept-5-en-2-ylmethanol 
(2.5 g, 20 mmol) and pyridine (4 mL, 50 mmol) were dissolved in dry 
DCM (235 mL) under an argon atmosphere and stirred for 5 min. 
Then, 4-nitrophenyl chloroformate (6 g, 30 mmol) was added and the 
reaction was stirred at room temperature for 90 min. After quenching 
with 200 mL of saturated ammonium chloride solution, the water 
phase was extracted three times with 100 mL DCM each. The organic 
phases were united and dried over sodium sulfate and the solvent was 
removed under reduced pressure. The raw product was purified with 
column chromatography using silica and pentane:EtOAc as solvent 
system (10:1; Rf = 0.6 in pentane:EtOAc 10:1). The product was obtained 
as a colorless solid and stored in the freezer (5.5 g, 87%). 1H NMR 
(700 MHz, CD3OD): δ 8.27 (m, 2 H, aryl), 7.43–7.34 (m, 2 H), 6.22–5.98 
(m, 2 H, R1HC = CHR2), 4.36–3.86 (m, 2 H, RCH2OCO2R), 2.96–2.80 
(m, 2 H, bridgehead-H), 2.57–2.46 (m, 1 H, R3R4CHCH2OR5), 1.94–0.58 
(m, 4 H, bridge-H atoms + R6CH2CR7CH2OR5). 13C NMR (176 MHz, 
CD3OD): δ 157.3, 154.1, 146.9, 139.0, 138.2, 137.3, 133.1, 126.3, 123.4, 
74.4, 73.8, 50.5, 45.9, 45.2, 44.9, 43.6, 42.9, 39.4, 39.1, 30.4, 29.8.
General Procedure for dPG-Dienophiles: All dPG-dienophiles were 
synthesized according to the same general procedure. As an example, 
dPG–norbonene is described in detail.
dPG-Norbonene9% (MM2): In a 50 mL Schlenk flask, dry DMF 
(15 mL) was added to a methanolic solution of dPG-amine (22.22 mL, 
0.09 g mL−1). Methanol was removed under reduced pressure, fresh dry 
DMF (15 mL) was added, the solution was constricted under reduced 
pressure to 25 mL and Et3N (0.82 g, 8.11 mmol, 1.12 mL) was added. 
Bicyclo[2.2.1]hept-5-en-2-ylmethyl (4-nitrophenyl) carbonate (0.94 g, 
2.97 mmol) (or other activated carbonate of dienophile) was dissolved 
in DMF (10 mL) and the solution was added dropwise via syringe to 
the dPG-amine solution. The resulting reaction mixture was stirred at 
room temperature overnight. The crude product was dialyzed against 
a mixture of water and acetone (1:1) for 3 days and methanol for 2 
days (MWCO = 1 kDa). The product was obtained as a slightly yellow 
methanolic solution (9% functionalization, 83%). 1H NMR (700 MHz, 
CD3OD, δ): 6.25–6.21 (m, 1 H, H-olefin), 6.05–6.00 (m, 1 H, H-olefin), 
3.98–3.48 (dPG-backbone), 2.98–2.92 (m, 1 H, H-bridgehead), 2.89–2.84 
(m, 1 H, H-bridgehead), 2.49–2.42 (m, 1 H, H-bridgehead), 1.94–1.88 
(m, 1 H, H-bridge), 1.51–1.47 (m, 1 H, H-bridge), 1.37–1.32 (m, 1 H, 
H-bridge), 0.64–0.59 (m, 1 H, H-ring). 13C NMR (176 MHz, CD3OD, δ): 
159.3, 138.6, 138.0, 137.4, 133.3, 81.4, 79.9, 74.0, 72.6, 72.4, 72.24, 70.7, 
69.4, 64.4, 62.8, 50.4, 49.9, 45.1, 44.9, 43.5, 42.8, 39.8, 39.5, 30.5, 29.9. 
IR (ATR): ν  = 3364, 2910, 2871, 1697, 1540, 1418, 1457, 1418, 1327, 
1254, 1107, 1076 cm−1.
dPG-BCN7.5% (MM1): dPG-BCN was synthesized according to a 
literature protocol. dPG-amine (22.22 mL, 0.09 g mL−1); Et3N (0.82 g, 
8.11 mmol, 1.12 mL); BCN (0.94 g, 2.97 mmol). The product was 
obtained as a yellow methanolic solution (7.5% functionalization, 
85%). 1H NMR (700 MHz, CD3OD, δ): 4.22–3.35 (dPG-backbone), 
2.47–2.12 (m, 4 H, H-vinyl), 1.72–1.32 (m, 4 H, H-ring), 1.04–0.93 (m, 
1 H, H-cyclopropane), 0.85–0.71 (m, 2 H, H-cyclopropane). 13C NMR 
(176 MHz, CD3OD, δ): 99.7, 81.5, 80.0, 74.0, 73.1, 72.6, 72.3, 72.3, 71.0, 
70.7, 64.5, 64.4, 63.0, 34.5, 30.3, 25.1, 24.2, 22.1, 21.4. IR (ATR): ν  = 
3379, 2915, 2873, 1696, 1614 1517, 1457, 1394, 1304, 1244, 1078, 934 
cm−1.
dPG-Cyclopropene8% (MM3): dPG-amine (5.55 mL, 0.09 g mL−1); 
Et3N (0.21 g, 2.03 mmol, 0.28 mL); (2-methylcycloprop-2-en-1-yl)methyl 
2-(4-nitrophenyl)acetate (0.22 g, 0.88 mmol). The product was obtained 
as a colorless methanolic solution (8% functionalization, 85%). 1H 
NMR (700 MHz, CD3OD, δ): 6.76–6.69 (m, 1 H, H-olefin), 3.97–3.46 (m, 
dPG-backbone), 2.25–2.15 (m, 3 H, methyl), 1.73–1.63 (m, 1 H, H-ring). 
13C NMR (176 MHz, CD3OD, δ): 122.2, 103.1, 81.5, 79.9, 74.0, 73.4, 
72.5, 72.2, 70.9, 70.7, 64.5, 64.4, 62.8, 18.4, 11.8. IR (ATR): ν = 3374, 
2912, 2876, 1697, 1541, 1457, 1325, 1259, 1110, 1080, 874, 848 cm−1. EA 
(C72H136N2O43): calc. C (50.34%), found C (50.36%); calc. N (1.63%), 
found N (2.45%); calc. H (7.98%), found (7.96%).
dPG-DHP9% (MM4): dPG-amine (5.55 mL, 0.09 g mL−1); Et3N (0.15 g, 
1.52 mmol, 0.21 mL); (3,4-dihydro-2H-pyran-2-yl)methyl (4-nitrophenyl) 
carbonate (0.16 g, 0.56 mmol). The product was obtained as a colorless 
methanolic solution (9% functionalization, 82%). 1H NMR (700 MHz, 
CD3OD, δ): 6.41–6.34 (m, 1 H, R1HC = CHOR2), 4.78–4.72 (m, 1 H, 
R3OHC = CHR1), 4.22–4.13 (m, 2 H, R4OCHR5R6), 4.07–3.44 (dPG-
backbone), 2.19–1.96 (m, 2 H, H-ring), 1.96–1.67 (m, 2 H, H-ring). 13C 
NMR (176 MHz, CD3OD, δ): 101.8, 101.7, 81.7, 81.5, 79.9, 74.5, 74.0, 
73.0, 72.5, 72.3, 71.0, 71.0, 70.7, 67.8, 64.5, 64.4, 62.7, 49.9, 25.3, 20.2. 
IR (ATR): ν  = 3384, 2913, 2874, 1701, 1650, 1541, 1457, 1418, 1329, 
1240, 1111, 1070 cm−1. EA (C726H1366N20O435): calc. C (50.30%), found 
C (48.86%); calc. N (1.62%), found (2.18%); calc. H (7.94%), found H 
(8.47%).
dPG-metTet6.5% (MM5): In a 250 mL Schlenk flask, dry DMF 
(50 mL) was added to a methanolic solution of dPG-amine (44.44 mL, 
0.09 g mL−1). Methanol was removed under reduced pressure, fresh 
dry DMF (50 mL) was added, and the solution was constricted under 
reduced pressure to 75 mL. The 4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzoic 
acid (0.89 g, 4.05 mmol), EDC·HCl (1.04 g, 5.41 mmol), HOBT (0.73 g, 
5.41 mmol), and DIPEA (1.05 g, 5.41 mmol, 1.38 mL) were dissolved in 
dry DMF (50 mL) and the solution was added dropwise via syringe to the 
Q8
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dPG-amine solution. The resulting reaction mixture was stirred at room 
temperature overnight. The crude product was dialyzed against DMF 
for 4 days and methanol for 4 days (MWCO = 1 kDa). The product was 
obtained as a red methanolic solution (6.5% functionalization, 85%). 1H 
NMR (700 MHz, CD3OD, δ): 8.69–8.53 (m, 2 H, H-aryl), 8.12–7.98 (m, 
2 H, H-aryl), 4.05–3.48 (m, dPG-backbone), 3.10 (s, 3 H, methyl-H).13C 
NMR (CD3OD, 176 MHz, δ): 169.4, 169.2, 164.8, 139.1, 136.3, 129.4, 
128.9, 81.7, 81.4, 80.2, 79.8, 74.0, 73.0, 72.5, 72.2, 71.0, 70.7, 70.3, 64.5, 
64.4, 62.8. IR (ATR): ν  = 3348, 2871, 1644, 1548, 1456, 1404, 1364, 1327, 
1305, 1258, 1070, 931 cm−1.
Macrogel Formation: The time required for the gelation of a mixture of 
dPG-metTet with the respective dPG-dienophile was measured. For each 
experiment, 50 µL of macromonomer solution was used (20 µL of dPG-
metTet + 30 µL of dPG-dienophile) at a concentration of 200 mg mL−1. 
The mixture was added to a small glass vial and after defined time 
spans, the vial was tilted at an angle of 45° to see if the mixture started 
to gelate. This was confirmed by the inability of the gels to flow down the 
glass vial. For samples that did not gelate even after 30 min, the time it 
took for the macromonomer mixture to flow from the top of the vial to 
the bottom of the vial was measured and compared to just dPG-metTet 
solution.
Nanogel Formation: General Procedure—The ratios of macromonomer 
A (dPG-metTet) to macromonomer B (dPG-dienophile) were set to 1:1.5. 
Acetone was utilized as the non-solvent. Parameters, such as solvent 
to non-solvent ratio (1:10–1:200), macromonomer concentration in 
water (0.5–7.5 mg mL−1), stirring speed (300–1200 rpm), chemical 
quenching time Tq,chem (0–∞ min), and water quenching time Tq,water 
(0–120 min) were varied according to the tables described in the results 
and discussion section, as well as the Supporting Information. As an 
example, a general procedure for one set of parameters is described 
below.
Macromonomers A and B were stored as stock-solutions in water. An 
aliquot was taken and separately diluted with water to a final volume 
of 1 mL. For this, 15 µL of macromonomer A were diluted with 485 µL 
water and 22.5 µL of macromonomer B with 477.5 µL water. Both 
solutions were cooled in an ice bath to 4 °C. Macromonomer A solution 
was added fast to solution B and shortly vortexed for 5 s. Then, the 
mixed solution was added very fast via syringe to a glass vial containing 
magnetically stirred acetone (40 mL) at 1200 rpm. The turbid dispersion 
was stirred for another 2 s and then kept still for 10 min. The reaction 
was then quenched by the addition of 20 µL of 2-(vinyloxy)ethan-
1-ol. Water (1/3 of acetone) was added after 30 min and the acetone 
was removed under reduced pressure. Purification was performed by 
centrifugal filtration, using a membrane with a cutoff of 300 kDa and 
three consecutive washing steps with 10 mL each. Nanogels were 
obtained as stable dispersions in water and characterized using DLS, 
NTA, and Zeta-potential measurements.
Coprecipitation of Myoglobin: The inverse nanoprecipitation was 
performed as described in Section 2.5. Varying amounts of a stock 
solution of myoglobin were added to the dPG-metTet macromonomer 
solution and thoroughly mixed. The total volume of water was kept at 
1 mL. 2.5 and 5 wt% of myoglobin were encapsulated each for dPG-
norbonene- and dPG-cyclopropene-NGs (n = 3). The gels were purified 
by centrifugation filtration, using filters with a molecular weight cutoff of 
1 MDa at 234 rcf. The gel volume was reduced to 1 mL and fresh PBS 
buffer solution was added (10 mL). Then, the volume was reduced to 
1 mL again and the whole process was repeated three times to ensure 
the complete removal of the nonencapsulated protein.
Protein Content Determination Assay: A standard Pierce BCA assay 
kit was used for the determination of protein content within the 
nanogels. 25 µL of the purified nanogels were added to a 96-well plate. 
Then, 200 µL of working reagent was added to each well and the plate 
was shaken for 30 s on a plate shaker. The plate was then incubated 
at 37 °C for 1 h. After cooling to room temperature, the absorbance 
was measured at 562 nm on a plate reader. Samples were recorded in 
triplicates and for three independent gels of the same type. Calibration 
curves were prepared for a dilution series of albumin and myoglobin 
in the range of 0–750 µg mL−1. Concentrations of myoglobin in the 
samples were determined via the fitted standard curves of myoglobin 
(Figure S6, Supporting Information).
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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Systematic Screening of Different Polyglycerin-based Dienophile Macromonomers for 
Efficient Nanogel Formation through IEDDA Inverse Nanoprecipitation 
 
Alexander Oehrl, Sebastian Schötz, Rainer Haag* 
 
Materials and Analytical Methods 
 
The solvents n-pentane, ethyl acetate, and diethyl ether were obtained from the technically pure 
solvents by distillation before use. DCM and acetone (HPLC grade) were used without further 
purification. Dry DCM and THF were taken from a SPS-800 type MBRAUN solvent drying 
system. Dry methanol and DMF were acquired from Acros and Fischer Chemical. All other 
chemicals and deuterated solvents were purchased and used without further purification. 
Qualitative thin layer chromatography (TLC) was performed on silica gel-coated aluminum 
plates serving as stationary phase (silica gel 60 F254 from Macherey-Nagel). The analytes were 
identified by irradiation of the TLC plates with UV light (λ = 254 nm) or by treatment with a 
potassium permanganate-based staining reagent (100 mL deionized water, 200 mg potassium 
permanganate) or anis aldehyde-based (450 mL EtOH, 25.0 mL anis aldehyde, 25.0 mL conc. 
sulfuric acid, 8.0 mL acetic acid). Column chromatography was performed with silica gel of 
Macherey-Nagel, grain size 40 – 63 μm, 230 - 400 mesh as the stationary phase, and the 
indicated eluent mixtures as mobile phase. IR spectra were recorded on a JASCO FT/IR-4100 
spectrometer. The characteristic absorption bands are given in wave numbers. 1H–NMR spectra 
were recorded at 300 K on Joel ECX 400 400 MHz and AVANCE III (700 MHz) instruments. 
Chemical shifts δ are indicated in parts per million (ppm) relative to tetramethyl silane (0 ppm) 
and calibrated as an internal standard to the signal of the incompletely deuterated solvent 
(CDCl3: δ = 7.26 ppm, MeOD: δ = 3.31 ppm). Coupling constants J are given in Hertz (Hz).  
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13C–NMR spectra were recorded at 300 K on AVANCE III instruments (176 MHz). Chemical 
shifts δ are given in parts per million (ppm) relative to tetramethyl silane (0 ppm) and calibrated 
as an internal standard to the signal of the incompletely deuterated solvent (CDCl3: δ = 77.16 
ppm, MeOD: δ = 49 ppm). Coupling constants J are given in Hertz (Hz). The spectra are 
decoupled from proton broadband. GPC was performed on an Agilent 1100 at 5 mg mL-1 using 
a pullulan standard,0.1 M NaNO3 solution as eluent, and a PSS Suprema column 10 μm with a 
flow rate of 1 mL/min. Signal was detected with an RI detector. DLS and Zeta potential were 
measured on a Malvern zeta- sizer nano ZS 90 with He–Ne laser (λ = 532 nm) at 173° 
backscatter and automated attenuation at 25 °C. Three measurements were performed per 
sample with between 10 and 16 individual measurements, yielding a mean size value plus 
standard deviation. Sample concentration was kept at 1 mg mL-1. The readout for the protein 




Activated carbonate precursors of the different dienophiles were partially synthesized 
according to literature-known procedures. Some procedures were modified as indicated. 




Scheme S1. Synthetic overview of the precursor molecules: (1) Rh-acetate dimer, ethyl 
diazoacetate, DCM, (2) LiAlH4, THF, (3) Br2, DCM, (4) KOtBu, THF, (5) 4-nitrophenyl 
chloroformate, py, DCM, (6) TBAF, THF and (7) acetamidine hydrochloride, hydrazine, 
Zn(OTf)2, then NaNO2, HCl. 
 




In a 2 L three-neck round bottom flask, cycloocatadiene (310 mL, 2.87 mol) and rhodium 
acetate dimer (750 mg, 1.72 mmol) were dissolved in 300 mL of dry DCM under an argon 
atmosphere. Ethyl diazoacetate (52.8 g, 458 mmol) dissolved in 150 mL dry DCM was then 
added dropwise to the magnetically stirred solution over the course of 8 h and the reaction 
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mixture was stirred at room temperature for 3 d. The solvent was removed under reduced 
pressure and the crude product was purified by column chromatography using hexane:EtOAc 
(100:1  50:1  20:1  5:1  0:1) as a solvent system (Rf (endo+exo) = 0.2/0.25 in 
Hex:EtOAc 5:1). The product (endo/exo-mixture) was obtained as a colorless liquid (85 g, 
95%).1H NMR (400 MHz, CDCl3, δ): 5.77 – 5.45 (m, 2 H), 4.20 – 3.94 (m, 2 H), 2.53 – 1.99 
(m, 6 H), 1.86 – 1.35 (m, 5 H), 1.23 (m, 3 H). 
 
(Z)-bicyclo[6.1.0]non-4-en-9-ylmethanol 
 OH  
In a dried 2 L three-neck round bottom flask, LiAlH4 (7.3 g, 193 mmol) was suspended in 250 
mL of dry diethylether under an argon atmosphere. The suspension was cooled to 0 °C using 
an ice bath. Ethyl (Z)-bicyclo[6.1.0]non-4-ene-9-carboxylate (25 g, 129 mmol) was dissolved 
in 250 mL of dry diethylether and added dropwise to the magnetically stirred solution over the 
course of 1 h using a dropping funnel. After complete addition, the reaction was warmed to 
room temperature and stirred for another hour. The reaction was then cooled to 0 °C again and 
carefully quenched with water until the precipitate turned white. After extraction with 3 x 300 
mL of diethylether, the organic phase was dried over sodium sulfate and the solvent was 
removed under reduced pressure. The product was obtained without further purification as a 
colorless liquid (20 g, quant.). 1H NMR (400 MHz, CDCl3, δ): 5.62 (td, J = 4.1, 1.9 Hz, 2H), 










In a dried 1 L Schlenk flask, (Z)-bicyclo[6.1.0]non-4-en-9-ylmethanol (20 g, 129 mmol) was 
dissolved in 450 mL of dry DCM under an argon atmosphere. The suspension was cooled to 
0 °C using an ice bath. Bromine (8 mL, 154 mmol) was dissolved in 50 mL of dry DCM and 
added dropwise to the magnetically stirred solution until the yellow color persisted. The 
reaction was quenched with 150 mL saturated sodium sulfite solution, turning the reaction 
mixture milky white. After extraction with 3 x 200 mL of DCM, the organic phase was dried 
over sodium sulfate and the solvent was removed under reduced pressure. The product was 
obtained without further purification as honey-like substance and used without further 
purification (42 g, quant.). 1H NMR (500 MHz, CDCl3, δ): 4.93 – 4.58 (m, 2 H), 3.87 – 3.34 
(m, 1 H), 2.77 – 2.50 (m, 2 H), 2.33 – 1.81 (m, 4 H), 1.70 – 1.02 (m, 3 H), 0.97 – 0.76 (m, 1 H), 





In a dried 2 L Schlenk flask, (4,5-dibromobicyclo[6.1.0]nonan-9-yl)methanol (42 g, 129 mmol) 
was dissolved in 250 mL of dry THF under an argon atmosphere. The suspension was cooled 
to 0 °C using an ice bath. KOtBu (48 g, 425 mmol) was suspended in 250 mL of dry THF and 
the supernatant was added dropwise to the magnetically stirred solution over the course of 8 h. 
The reaction was stirred at room temperature for 2 d and another 20 g of KOtBu was added 
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directly to the suspension. The reaction mixture was then stirred for another 2 d. After 
quenching with 200 mL of saturated ammonium chloride solution, the THF was removed under 
reduced pressure and the water phase was extracted 3 times with 300 mL DCM each. The 
organic phases were united and dried over sodium sulfate and the solvent was removed under 
reduced pressure. The raw product was purified with column chromatography using silica and 
hexane:EtOAc as solvent system (100:1  50:1  20:1  5:1  2:1). The product was 
obtained as a slightly yellow liquid (7 g, 37%). 1H NMR (500 MHz, CDCl3, δ): 4.93 – 4.58 (m, 
2 H), 3.87 – 3.34 (m, 1 H), 2.77 – 2.50 (m, 2 H), 2.33 – 1.81 (m, 4 H), 1.70 – 1.02 (m, 3 H), 
0.97 – 0.76 (m, 1 H), 0.74 – 0.57 (m, 1 H). 
 






In a dried 2 L Schlenk flask, bicyclo[6.1.0]non-4-yn-9-ylmethanol (7 g, 47 mmol) and pyridine 
(9,5 mL, 117 mmol) were dissolved in 750 mL of dry DCM under an argon atmosphere and 
stirred for 5 min. Then 4-nitrophenyl chloroformate (14.1 g, 70 mmol) was added and the 
reaction was stirred at room temperature for 90 min. After quenching with 200 mL of saturated 
ammonium chloride solution, the water phase was extracted 3 times with 300 mL DCM each. 
The organic phases were united and dried over sodium sulfate and the solvent was removed 
under reduced pressure. The raw product was purified with column chromatography using silica 
and pentane:EtOAc as solvent system (20:1  10:1; Rf = 0.7 in pentane:EtOAc 3:1). The 
product was obtained as a colorless solid and stored in the freezer (11.4 g, 78 %).1H NMR (400 
MHz, CDCl3, δ): 8.32 – 8.23 (m, 2 H), 7.43 – 7.33 (m, 2 H), 5.30 (d, J = 0.7 Hz, 1 H), 4.40 (dd, 
J = 8.2, 0.7 Hz, 1 H), 4.21 (dd, J = 6.8, 0.7 Hz, 1 H), 2.45 (dd, J = 13.3, 2.9 Hz, 1 H), 2.39 – 
46
2.24 (m, 3 H), 2.29 – 2.12 (m, 2 H), 1.60 (d, J = 10.9 Hz, 1 H), 1.50 (td, J = 9.0, 8.3 Hz, 1 H), 






In a dry 1 L three-neck round bottom flask, LiAlH4 (7.3 g, 193 mmol) was suspended in 300 
mL of dry diethylether under an argon atmosphere. The suspension was cooled to 0 °C using 
an ice bath. Bicyclo[2.2.1]hept-5-ene-2-carbaldehyde (5 g, 129 mmol) was dissolved in 30 mL 
of dry diethylether and added dropwise to the magnetically stirred solution over the course of 
1 h using a dropping funnel. After complete addition, the reaction was warmed to room 
temperature and stirred for another hour. The reaction was then cooled to 0 °C again and 
carefully quenched with water until the precipitate turned white. After extraction with 3 x 250 
mL of diethylether, the organic phase was dried over sodium sulfate and the solvent was 
removed under reduced pressure. The product was obtained without further purification as a 
colorless liquid (5.5 g, 93%). 1H NMR (400 MHz, CDCl3, δ): 6.06 (dd, J = 5.8, 3.0 Hz, 1H, 
RCH=CHR), 5.89 (dd, J = 5.8, 2.9 Hz, 1H, RCH=CHR), 3.60 (m, 1H, CH2OH), 3.28 (m, 1H, 
CH2OH), 2.86 (s, 1H, bridgehead), 2.72 (s, 1H, bridgehead), 2.31 – 2.11 (m, 1H, R2CHCH2OH), 
1.74 (ddd, J = 11.6, 9.2, 3.8 Hz, 1H, ), 1.44 – 1.33 (m, 1H), 1.32 – 1.17 (m, 1H), 0.43 (ddd, J = 

















In a 100 mL three-neck round bottom flask, trimethylsilylpropyne (6.5 g, 58 mmol) and 
rhodium acetate dimer (25 mg, 0.06 mmol) were dissolved in dry DCM (30 mL) under an argon 
atmosphere. Ethyl diazoacetate (4 g, 35 mmol), dissolved in 20 mL dry DCM was then added 
dropwise to the magnetically stirred solution over the course of 8 h and the reaction mixture 
was stirred at room temperature for 1 d. The solvent was removed under reduced pressure and 
the crude product was purified by column chromatography using pentane:EtOAc (100:1) as a 
solvent system. Further purification was performed using HPLC. The product was obtained as 
a colorless liquid (2.37 g, 34%). 1H NMR (400 MHz, CDCl3, δ): 5.77 – 5.45 (m, 2 H), 4.20 – 





In a 50 mL Schlenk flask, DIBAL–H (10.08 mmol, 10.08 mL, 1.0 M in THF) was dissolved in 
dry Et2O (25 mL). The ethyl 2-methyl-3-(trimethylsilyl)cycloprop-2-ene-1-carboxylate 
(1.00 g, 5.05 mmol) was added dropwise with a syringe. The solution was stirred at room 
temperature for 30 minutes. Saturated aqueous solution of Rochelle’s salt (10 mL) was added. 
The phases were separated and the aqueous phase was extracted with Et2O (3x10 mL). The 
combined organic phases were dried with sodium sulfate. The solvent was removed under 
reduced pressure. The crude product was purified by column chromatography (DCM/EtOAc, 
10:1) to give the product as a colorless oil (0.59 g, 3.80 mmol, 75%). 1H NMR (400 MHz, 
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CDCl3, δ): 3.48 (d, J = 4.6 Hz, 2H, HOCH2R1), 2.21 (s, 3H, methyl-H), 1.56 (t, J = 4.6 Hz, 1H; 
HOCH2CHR2R3), 0.17 (s, 9H, TMS-H). 
 





In a 100 mL Schlenk flask, (2-methyl-3-(trimethylsilyl)cycloprop-2-en-1-yl)methanol (0.67 g, 
4.28 mmol) was dissolved in THF (45 mL). TBAF (5.00 mL, 1.4 M in THF) was added and the 
solution was stirred for 30 min at room temperature. Water and DCM were added, the phases 
separated, and the aqueous phase was extracted with DCM (3x40 mL). The combined organic 
phases were dried with sodium sulfate. The solvent was removed under reduced pressure. The 
crude product was purified by a short silica pad. Without any further purification, the desilylated 
cyclopropene was dissolved in dry DCM (40 mL) and pyridine (0.21 g, 2.63 mmol, 0.21 mL) 
was added. The solution was stirred for 5 min at room temperature. p-nitrophenylchloroformate 
(0.32 g, 1.58 mmol) was added and the resulting solution was stirred for 45 min at room 
temperature. Saturated aqueous NH4Cl-solution was added, and the phases were separated. The 
aqueous phase was extracted with DCM (3x40 mL). The combined organic phases were washed 
with saturated aqueous NH4Cl-solution and dried with sodium sulfate. The solvent was 
removed under reduced pressure. The crude product was purified by column chromatography 
(pentane/EtOAc, 10:1). The product (0.19 g, 0.77 mmol, 73% over 2 steps) was obtained as a 
yellow oil. 1H NMR (400 MHz, CDCl3, δ): 8.30–8.26 (m, 2 H H–aromatic), 7.41–7.37 (m, 2 H, 
aromatic), 6.61 (s, 1 H, H–olefin), 4.32–4.12 (m, 2 H, aliphatic), 2.17 (s, 3 H, Me), 1.79–1.76 
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(m, 1 H, H–ring). EA (C12H11NO5): calc. C (57.83%), found C (58.45%); calc. N (5.62%), 
found N (5.75%); calc. H (4.45%), found H (4.55%). 
 






In a 250 mL Schlenk flask, (3,4-dihydro-2H-pyran-2-yl)methanol (2.00 g, 17.52 mmol) was 
dissolved in dry DCM (80 mL) and pyridine (3.46 g, 43.81 mmol, 3.53 mL) was added. The 
solution was stirred for 5 min at room temperature. p-nitrophenylchloroformate (5.30 g, 
26.28 mmol) was added and the resulting solution was stirred for 45 min at room temperature. 
Saturated aqueous NH4Cl-solution was added and the phases were separated. The aqueous 
phase was extracted with DCM (3x40 mL). The combined organic phases were washed with 
saturated aqueous NH4Cl solution and dried with sodium sulfate. The solvent was removed 
under reduced pressure. The crude product was purified by column chromatography 
(pentan/EtOAc, 10:1). The product (3.44 g, 13.78 mmol, 79%) was obtained as a yellow solid. 
1H NMR (400 MHz, CDCl3, δ): 8.30–8.26 (m, 2 H, H–aromatic), 7.42–7.38 (m, 2 H, H–
aromatic), 6.42–6.39 (m, 1 H H–olefin-O), 4.78–4.73 (m, 1 H, H–olefin),  4.38 (d, J = 5.2 Hz, 
2 H, H–C–carbonate), 4.19–4.13 (m, 1 H, H–C(tertiary)), 2.20–1.71 (m, 4 H, H–ring). 13C NMR 
(176 MHz, CD3OD, δ): 157.1, 154.0, 146.9, 144.2, 126.3, 123.2, 101.7, 73.7, 71.70, 24.9, 20.1. 
EA (C13H13NO6): calc. C (55.92 %), found C (55.96 %); calc. N (4.69 %), found N (5.25 %); 
calc. H (4.77 %), found H (4.77 %). 
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4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzoic acid was synthesized according to a modified 
literature protocol.[4] 
 




4-cyanobenzoic acid (1.5 g, 10 mmol), acetamidine hydrochloride (4.82 g, 41 mmol) and 
Zn(OTf)2 (1 g, 3 mmol) were ground in a mortar, added to a 100 mL Schlenk flask under argon 
atmosphere, and cooled to 0 °C. Anhydrous hydrazine (12 mL, 377 mmol) was then slowly 
added under constant stirring; the reaction mixture was allowed to warm to room temperature 
and stirred for 72 h. NaNO2 (10 g) dissolved in 30 mL of water was then added to the reaction 
mixture. After cooling to 0 °C, the pH was adjusted to 2-3 by the slow addition of conc. HClaq. 
The color of the solution turned bright pink and a pink solid precipitated. After stirring at 0 °C 
for another 1 h, the precipitate was filtered and washed with deionized water and MeOH. The 
product was obtained as a pink solid without further purification (1.1 g, 50 %). 1H NMR (400 
MHz, C3D7NO, δ): 13.80 (s, 1 H, COOH), 8.67 – 8.65 (m, 2 H, ArH), 8.32 – 8.29 (m, 2 H, 




dPG and dPG-amine were synthesized according to literature protocols.[5,6] 
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 Figure S1. GPC-analysis of the dPG core. 





Size by Volume 
[nm] 
PDI 
dPG-BCN 7.5 12 ± 2 0.30 ± 0.01 
dPG-norbonene 9 4 ± 1 0.80 ± 0.02 
dPG-DHP 9 3 ± 1 0.60 ± 0.05 
dPG-metTet 6.5 160 ± 140 0.50 ± 0.01 


























1 1:1.5 5 1:40 none 120 192 ± 5 0.07 ± 0.04 
2 1:1.5 5 1:40 30 120 191 ± 3 0.07 ± 0.01 
3 1:1.5 5 1:40 10 120 211 ± 2 0.11 ± 0.01 
4 1:1.5 5 1:40 5 120 180 ± 1 0.07 ± 0.02 
5 1:1.5 5 1:40 2.5 120 185 ± 3 0.08 ± 0.02 
6 1:1.5 5 1:40 1 120 203 ± 1 0.10 ± 0.01 
7 1:1.5 5 1:40 0 120 175 ± 1 0.08 ± 0.02 
A = dPG-metTet, B = dPG-norbonene 
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 Figure S2. Relationship between chemical quenching time and size of nanogels. 
 




















1 1:1.5 5 1:40 10 60 300 150 ± 30 0.07 ± 0.03  
2 1:1.5 5 1:40 10 60 600 119 ± 7 0.04 ± 0.01 
3 1:1.5 5 1:40 10 60 900 140 ± 30 0.07 ± 0.03 
4 1:1.5 5 1:40 10 60 1200 130 ± 40 0.07 ± 0.04 
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A = dPG-metTet; B = dPG-norbonene. 
 
Figure S3. Dependency of nanogel size on stirring speed during nanoprecipitation. 
 















1 1:1.5 5 1:80 5 30 a 1 
2 1:1.5 5 1:60 5 30 a 1 
3 1:1.5 5 1:40 5 30 800 ± 23 0.20 ± 0.03 
4 1:1.5 5 1:20 5 30 132 ± 2 0.07 ± 0.04 
























1a 1:1.5 5 1:40 5 2 950 ± 150 0.34 ± 0.02 
2a 1:1.5 5 1:40 5 5 1800 ± 300 0.50 ± 0.02 
3a 1:1.5 5 1:40 5 10 2300 ± 500 0.80 ± 0.30 
4 1:1.5 5 1:40 5 30 359 ± 7 0.20 ± 0.05 
a = Quality criteria for DLS measurements not fulfilled. 
 
 
















1 1:1.5 5 1:40 5 5 78 ± 1  0.10 ± 0.01 
2 1:1.5 5 1:40 5 30 81 ± 1 0.06 ± 0.01 
3 1:1.5 5 1:40 5 60 101 ± 2 0.10 ± 0.01 
4 1:1.5 5 1:20 5 30 76 ± 1 0.15 ± 0.01 
5 1:1.5 5 1:40 5 30 93 ± 2 0.10 ± 0.01 
6 1:1.5 5 1:60 5 30 124 ± 2 0.07 ± 0.01 








Figure S4. Zeta potential measurements of dPG-norbonene-, dPG-cyclopropene-, and dPG-
BCN-NGs. Average of 3 measurements +SD.  
 













1 1:1.5 5 5 265 ± 5 0.07 ± 0.02 
2 1:1.5 5 5 435 ± 5 0.10 ± 0.02 
3 1:1.5 5 2.5 191 ± 1 0.04 ± 0.02 
4 1:1.5 5 2.5 241 ± 2 0.04 ± 0.03 
A = dPG-metTet, B = dPG-norbonene, V(H2O):V(acetone) = 1:40, Tq, chem = 10 min and 

















1 1:1.5 5 5 185 ± 2 0.04 ± 0.02 
2 1:1.5 5 5 185 ± 2 0.08 ± 0.02 
3 1:1.5 5 2.5 154 ± 1 0.07 ± 0.01 
4 1:1.5 5 2.5 182 ± 3 0.07 ± 0.01 
A = dPG-metTet, B = dPG-cyclopropene, V(H2O):V(acetone) = 1:40; Tq, chem = 10 min and 






 Figure S5. NTA measurements for the nanogels shown in Figure 4. (A) dPG-norbonene NG, 
(B) dPG-cyclopropene NG and (C) dPG-BCN NG. Measurements performed in triplicate at 



















BCA Protein Assay 
 
Figure S6. Albumin calibration curve. 
 
Figure S7. Calibration curve of myoglobin. 
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3.2 Synthesis of pH-Degradable Polyglycerin-Based Nanogels by iEDDA-
Mediated Crosslinking for Encapsulation of Asparaginase Using Inverse 
Nanoprecipitation 
 
Alexander Oehrl, Sebastian Schötz, Rainer Haag, Colloid Polym. Sci, submitted 
 
Abstract 
Biocompatible, environmentally responsive, and scalable nanocarriers are needed for targeted 
and triggered delivery of therapeutic proteins, such as the anticancer protein asparaginase are 
needed. For this purpose, suitable polymer scaffolds, preparation methods and crosslinking 
chemistries have to be considered. Good options include, biocompatible dendritic 
polyglycerol (dPG) as the polymer, the mild surfactant-free inverse nanoprecipitation method 
for nanogel preparation, and the fast, bioorthogonal, and scalable inverse electron demand 
Diels-Alder (iEDDA) as a crosslinking chemistry. In this work, the synthesis of pH-
degradable nanogels, based on tetrazine, norbonene and bicyclo[6.1.0]nonyne (BCN) 
functionalized macromonomers is reported. Cell viability assays show the cell-compatibility 
of the macromonomers at concentrations of up to 2.5 mg mL-1 for three different cell lines. 
Nanogels are obtained in the size range of 47 to 200 nm and can be degraded within 48 h at 
pH 4.5 for the benzacetal (BA) nanogels, and at pH 3 for the tetrahydropyran (THP) based 
nanogels. Encapsulation of the therapeutic protein asparaginase (32 kDa) yield encapsulation 
efficiencies of up to 93% at 5 wt.% feed. Overall, iEDDA crosslinked pH-degradable dPG-
nanogels from inverse nanoprecipitation are promising candidates for biomedical 
applications. 
 
Contributions: Study design, synthesis of precursors and parts of macromonomers, synthesis 
and characterization of nanogels, protein encapsulation and protein determination assay, 
degradation studies with loaded nanogels, manuscript preparation, manuscript revision. 
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Abstract
Biocompatible, environmentally responsive, and scalable nanocarriers are needed for targeted 
and triggered delivery of therapeutic proteins. Suitable polymers, preparation methods and 
crosslinking chemistries must be considered for nanogel formation. Biocompatible dendritic 
polyglycerol (dPG) is used in the mild, surfactant-free inverse nanoprecipitation method for 
nanogel preparation. The biocompatible, fast, and bioorthogonal inverse electron demand 
Diels-Alder (iEDDA) crosslinking chemistry is used. In this work, the synthesis of pH-
degradable nanogels, based on tetrazine, norbonene and bicyclo[6.1.0]nonyne (BCN) 
functionalized macromonomers is reported. The macromonomers are non-toxic up to 2.5 mg 
mL-1 in three different cell lines. Nanogels are obtained in the size range of 47 to 200 nm and 
can be degraded within 48 h at pH 4.5 (BA-gels), and pH 3 (THP-gels), respectively. 
Encapsulation of asparaginase (32 kDa) yield encapsulation efficiencies of up to 93% at 5 wt.% 
feed. Overall, iEDDA crosslinked pH-degradable dPG-nanogels from inverse nanoprecipitation 
are promising candidates for biomedical applications.
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1. Introduction
Modern medicine has a high demand for new and smart nanocarrier systems for drug delivery, 
that improve pharmacokinetics, permit the use of less overall drug, thus reduce side effects, 
lead to prolonged drug circulation time, and can deliver their cargo specifically to diseased 
tissue and not to healthy tissue.[1] Additionally, these carrier systems must be biocompatible 
and either biodegradable or be easily excreted by the body after delivering their cargo.[2, 3] 
Any degradation products and metabolites must be non-toxic. Attempts have been made to 
design such nanocarriers for a variety of drugs. In the class of hydrophobic drugs there are 
already some examples on the market, such as liposomal formulations of the anticancer drugs 
doxorubicin (Doxil®) and daunorubicin (DaunoXome®), and micellar estradiol 
(Estrasorb™)[4]. However, liposomal formulations cannot be considered smart or responsive 
carriers, as they lack the structural properties to respond to external stimuli. For the more 
sensitive drugs, such as therapeutic proteins, liposomal formulations are not very suitable. The 
detergent nature of the liposomes can disrupt the natural folding of the proteins and thus lead 
to a loss of function. However, especially this type of drug needs improved delivery systems. 
Proteins are usually injected intravenously to the body, due to low stability in the strongly acidic 
environment of the stomach or due to very low absorption within the small intestine.[5] In the 
blood stream, the mononuclear phage system (MPS), a part of the immune system, effectively 
removes foreign substances from the body. Proteins are easily recognized by the MPS and are 
thus eliminated quite fast.[4, 6, 7] Apart from the MPS, small proteins are also excreted via the 
kidney if their molecular weight is below the renal threshold of 45 kDa or hydrodynamic 
diameter of 5.5 nm.[8–10] This shows, that nanocarriers are needed for protein delivery, which 
are able to increase the total molecular weight of the therapeutics to prolong circulation times 































































and offer evasion from the MPS clearance. Currently, the only type of carriers that fulfill these 
criteria and are on the market, are polyethylene glycol (PEG) protein conjugates. PEG is a 
hydrophilic and size-tunable, biocompatible polymer that is attached randomly, or site specific 
to the protein. This increases the total molecular weight above the renal threshold and leads to 
increased circulation times and reduced clearance through the MPS.[11–13] However, recently 
PEG has shown to be able to induce immune responses in some patients, leading to reduced 
effectivity of the treatment.[14, 15] Furthermore, targeted delivery is not possible with PEG 
conjugation and can also reduce the activity of the protein that it is conjugated to. Thus, 
alternatives that provide the same advantages as PEG, but additionally also allow for a targeted 
delivery and release of the protein are needed. 
Alternatively nanogels consist of hydrophilic polymer networks in the size range of 10 
to 1000 nm and offer a hydrophilic environment that shields any cargo encapsulated inside.[16–
21] The properties of these gels can be tuned, based on the polymers that are used for the 
network formation. A variety of options exist and have been intensively studied. Natural 
polymers such as e.g. alginate[22], dextran[23] and chitosan[24] have been used for nanogel 
preparation. However, synthetically easily accessible polymers such as PEG[25], copolymers 
of polylactic and glycolic acid (PLA/PLA-co-PGA)[26], linear polyglycerol (lPG)[27] and 
dendritic polyglycerol (dPG)[27–30] have also been successfully used for nanogel formation. 
The introduction of environmentally responsive groups, such as pH-sensitive acetals[31–33], 
or redox-sensitive disulfides[16, 34] can then be used for the preparation of degradable 
nanogels. For example, within endosomes and lysosomes, the pH value drops to values between 
4 and 6.[35]
Beside network material, the preparation method also has ab big influence on the 
suitability of the carrier for biomedical applications. Nanogels have been prepared by methods 
such as micro- and miniemulsion polymerization.[23, 36–38] However, the use of surfactants, 































































heat, and ultrasound can be detrimental for the encapsulation of sensitive biotherapeutics. 
Furthermore, surfactants are sometimes hard to remove and can have a negative impact on cell 
viability and applicability in vitro and in vivo. 
Technologies such as the nanoprecipitation method, where nanoparticles are formed by 
precipitation in their corresponding non-solvent water have been adjusted to hydrophilic 
macromonomers.[39–42] This inverse nanoprecipitation leads to hydrophilic nanogels by 
precipitation of the macromonomers in solvents like acetone. Thus, very mild conditions for 
the encapsulation of proteins are present, as no surfactants or ultrasound are used.[28, 30] 
For the inverse nanoprecipitation method, usually macromonomers are used, that 
crosslink in situ during the precipitation process. In order to have a reasonably fast gelation, the 
type of crosslinking chemistry plays a major role for successful preparation of nanogels. 
Suitable chemistries include the click-type copper catalyzed azide alkyne cycloaddition 
(CuAAC)[30], the strain promoted version of CuAAC (SPAAC)[27], Thio-Michael 
addition[43], and inverse electron demand Diels-Alder (iEDDA). CuAAC is suitable for gel 
formation, however, the toxic copper ions are hard to remove and can have toxicity in vivo. 
Thio-Michael addition is fast and scalable, however, not suitable for proteins containing thiols, 
as a cross-reactivity exists. SPAAC offers a fast gelation, as well as very low cross-reactivity 
with free thiols. However, the synthetic precursors are expensive and exhibit low yielding, long 
synthetic procedures. In contrast, iEDDA reactions between tetrazine derivatives and 
dienophiles are so fast and bioorthogonal[44–47], that they have been used for fluorescent 
labeling of antibodies,[48] DNA-tagging,[49] and even cell labeling.[50] The synthetic 
precursors are inexpensive and prepared in a straightforward manner. Depending on the 
application, one can choose between different reactivities and thus gelation times. As there are 
no side reactions with biological systems, this method is one of the most bioorthogonal 
reactions available so far. Furthermore, no toxic catalysts, such as copper ions are needed, 































































which makes iEDDA a very promising coupling strategy for the preparation of biocompatible 
nanogels.
We present the synthesis of new pH-cleavable macromonomers based on the 
biocompatible and easy to functionalize dPG[12, 51–53] with methyl-tetrazine and the 
dienophiles norbonene and bicyclo[6.1.0]non-4-yne (BCN) as iEDDA reactive functional 
groups. pH-degradability is introduced by incorporation of benzacetal (BA) and 
tetrahydropyran-based (THP) acetals into the macromonomers which cleave at pH values of 5 
and 3, respectively. The macromonomers are characterized by NMR, IR and DLS and tested 
regarding their ability to form stable nanogels during inverse nanoprecipitation in acetone under 
various reaction conditions. dPG-BA-norbonene and dPG-THP-norbonene are used for 
encapsulation of the therapeutic protein asparaginase with excellent encapsulation efficiencies 
of up to 93%. The BA-based gels are cleaved completely within 48 h at pH 4.5, while the THP-
based gels were degraded at pH 3 within 48 h. The macromonomers were tested in a cell 
viability assay with three different cell lines and did not show toxicity up to about 2.5 mg mL-
1.
The fast and efficient synthetic route to pH-cleavable macromonomers with iEDDA 
reactive groups, as well as the stable and scalable nanogels that are obtained from them, while 
avoiding the drawbacks of toxic catalysts or side reactivity in other crosslinking strategies, 
makes this a nanocarrier system with potential biomedical application.































































2. Materials and Methods
2.1 Materials
Ethyl acetate, n-pentane and diethyl ether were obtained from the technically pure solvents by 
distillation before use. Dry DCM and THF were used from a SPS-800 type MBRAUN solvent 
drying system. Acetone and DCM (HPLC grade) were used without further purification. Dry 
methanol and DMF were purchased from Acros and Fischer Chemical. All other chemicals and 
deuterated solvents were obtained from Sigma Aldrich, Acros, Merck, and Fisher Chemicals 
and were used as without further purification. Thin layer chromatography (TLC) was performed 
on silica gel-coated aluminum plates, serving as stationary phase (silica gel 60 F254 from 
Macherey-Nagel). Identification of analytes was done by UV-irradiation (λ = 254 nm) of the 
TLC plates or by treatment with a potassium permanganate-based (100 mL deionized water, 
200 mg potassium permanganate) or anis aldehyde-based staining solution (450 mL EtOH, 25 
mL anis aldehyde, 25 mL conc. sulfuric acid, 8.0 mL acetic acid). Column chromatography was 
performed with silica gel (Macherey-Nagel, grain size 40 - 63 μm, 230 - 400 mesh) as stationary 
phase and the indicated eluent mixtures as the mobile phase.
2.2 Analytical Methods
IR spectra were recorded on a JASCO FT/IR-4100 spectrometer. The characteristic absorption 
bands are given in wave numbers. 1H NMR spectra were recorded at 300 K on Joel ECX 400 
400 MHz and AVANCE III (700 MHz) instruments. Chemical shifts δ are indicated in parts 
per million (ppm) relative to tetramethyl silane (0 ppm) and calibrated as an internal standard 
to the signal of the incompletely deuterated solvent (CDCl3: δ = 7.26 ppm, MeOD: δ = 
3.31 ppm). Coupling constants J are given in Hertz (Hz). 13C NMR spectra were recorded at 
300 K on AVANCE III instruments (176 MHz). Chemical shifts δ are given in ppm relative to 
tetramethyl silane (0 ppm) and calibrated as an internal standard to the signal of the 































































incompletely deuterated solvent (CDCl3: δ = 77.16 ppm, MeOD: δ = 49 ppm). Coupling 
constants J are given in Hertz (Hz). The spectra are decoupled from proton broadband. DLS 
and Zeta potential were measured on a Malvern zeta- sizer nano ZS 90 with He–Ne laser (λ = 
532 nm) at 173° backscatter and automated attenuation at 25 °C. Three measurements were 
performed per sample, yielding a mean size value plus standard deviation. Sample 
concentration was kept at 1 mg mL-1. GPC was performed on an Agilent 1100 at 5 mg mL-1 
using a pullulan standard, 0.1 M NaNO3 solution as eluent and a PSS Suprema column 10 μm 
with a flow rate of 1 mL min-1. Signals were detected with an RI detector. 
2.3 Precursors and Macromonomers
All air- and moisture-sensitive reactions were carried out in flasks in an inert atmosphere 
(argon) using conventional Schlenk techniques. Reagents and solvents were added via argon 
rinsed syringes. Solids were added in argon counterflow as solutions in the corresponding 
solvent.
The synthesis of the literature known precursors is described in the Supporting 
Information, showing the modified procedures. 
2-(azidomethyl)-3,4-dihydro-2H-pyran (5)
(3,4-dihydro-2H-pyran-2-yl)methanol (1.58 g, 13.84 mmol) and Et3N (2.10 g, 20,76 mmol, 
2.88 mL) were dissolved in DCM (25 mL). Methane sulfonyl chloride (1.74 g, 15.23 mmol, 
1.18 mL) was added dropwise via syringe. The solution was stirred for 45 minutes at 0 °C. 
Saturated aqueous NaHCO3-solution was added, phases were separated, and the aqueous phase 
was extracted with DCM (3x25 mL). The combined organic layers were dried with Na2SO4. 
The solvent was removed under reduced pressure. 































































The crude product (2.84 g, 14.77 mmol) was dissolved in DMF (20 mL) and NaN3 (9.60 g, 
147.67 mmol) was added. The solution was stirred at 55 °C for three days. Water (20 mL) was 
added, the phases were separated, and the aqueous phase was extracted with DCM (3x25 mL). 
The combined organic layers were dried with Na2SO4. The solvent was removed under reduced 
pressure. The crude product was purified by column chromatography (pentan/EtOAc, 10:1) to 
give the product (30) (1.91 g, 13.76 mmol, 93 % over 2 steps) as a colorless oil. 
1H–NMR (400 MHz, CD3OD): δ = 6.38 (d, J = 6.2 Hz, 1 H, H–olefin–O), 4.74–4.72 (m, 1 H, 
H–olefin), 4.01–3.96 (m, 1 H, H–tertiary), 3.48–3.32 (m, 2 H, H–CN3), 2.16– 1.58 (m, 4 H, H–
ring) ppm.
dPG-THP-azide5%
dPG (0.12 g, 1.44 mmol) was dried under HV at 70 °C overnight and dissolved in dry DMF (10 
mL). The DHP-azide (5) (0.02 g, 0.15 mmol) was dissolved in dry DMF (5 mL) and added to 
the dPG–solution via syringe and p-TSA (1.90 μg, 0.01 mmol) was added. The resulting 
solution was stirred at room temperature overnight. After quenching with a small excess of 
NEt3 the crude product was constricted under reduced pressure and dialyzed against H2O and 
methanol 1:1 for 4 days and methanol for 3 days (MWCO = 1 kDa). The product was obtained 
as methanolic solution (5.0% functionalization, 85%). 
1H–NMR (700 MHz, CD3OD): δ = 4.59–4.53 (m, 1 H, H–C2H2N3), 4.21–14 (m, 1 H, H–C2H2–
carbamate), 4.04 (dPG – backbone), 3.33–3.20 (m, 2 H, H–C–carbamate), 1.99–1.39 (m, 6 H, 
H–ring) ppm. 
13C–NMR (176 MHz, CD3OD): δ = 101.4, 80.0, 79.9, 79.5, 79.3, 79.1, 74.1, 74.0, 72.6, 72.5, 
72.2, 70.7, 70.67, 64.5, 64.4, 33.1, 29.1 ppm. 
IR (ATR): ν̃ = 3375, 2919, 2871, 2357, 2332, 2099, 1649, 1450, 1324, 1300, 1261, 1067 cm-
1. 































































EA (C66H31N3O42): calc. C (48.37%), found C (49.46%); calc. N (2.56%), found N 
(2.62%), calc. H (8.06%), found H (8.47%). 
dPG-THP-amine5%
The dPG-THP-azide (1.67 g, 22.21 mmol, 1.13 mmol azide) was dissolved in THF (70 mL). 
Distilled water (80 mL) and PPh3 (3.50 g, 13.33 mmol) were added and the solution was stirred 
for seven days at room temperature. THF was removed under reduced pressure and the crude 
product was filtered. The filtrate was constricted under reduced pressure. The crude product 
was dialyzed against methanol for 5 days (MWCO = 1 kDa). The product was obtained as a 
methanolic solution (5.0% functionalization, 95%). 
1H–NMR (700 MHz, CD3OD): δ = 4.76–4.65 (m, 2 H, H–acetal), 4.24–4.03 (m, 2 H, H–
C2H6N), 4.00–3.43 (dPG – backbone), 2.96–2.68 (m, 2 H, H–tertiary), 2.02–1.17 (m, 6 H, H–
ring) ppm. 
13C–NMR (176 MHz, CD3OD): δ = 170.3, 142.7, 103.3, 81.7, 81.4, 80.2, 79.9, 73.98, 74.0, 
73.0, 72.4, 72.2, 71.0, 70.7, 70.7, 64.5, 64.4, 62.8, 49.4 ppm. 
IR (ATR): ν̃ = 3359, 2913, 1871, 2380, 1650, 1456, 1327, 1067, 1030, 931, 866. 748 cm -1.
General Procedure for dPG-dienophiles
All dPG-dienophiles were synthesized according to the same general procedure. As an example, 
dPG-BA-norbonene is described in detail.
dPG-BA-norbonene8% (MM4)
Dry DMF (7.50 mL) was added to a methanolic solution of dPG–benzacetal-amine (10.00 mL, 
0.062 g/mL). Methanol was removed under reduced pressure. Fresh dry DMF (7.50 mL) was 
added, the solution was constricted under reduced pressure to 15 mL and Et3N (0.18 g, 1,83 































































mmol, 0.25 mL) was added. Norbonene active carbonate (2) (0.19 g, 0.67 mmol) was dissolved 
in DMF (10 mL) and the solution was added dropwise via syringe to the dPG – amine solution. 
The resulting reaction mixture was stirred at room temperature overnight. The crude product 
was dialyzed against a mixture of water and acetone (1:1) and methanol for 4 days (MWCO = 
1 kDa). The product was obtained as a yellow methanolic solution (88%, 7.5 % 
functionalization). 
1H–NMR (700 MHz, CD3OD): δ = 7.49–7.35 (m, 2 H, H–aromatic), 7.02–6.88 (m, 2 H, H–
aromatic), 6.20–6.06 (m, 1 H, H–olefin), 5.99–5.84 (m, 1 H, H–olefin), 5.78–5.68 (m, 1 H, H–
acetal), 4.63–4.54 (m, 2 H, H–C–carbamate), 4.47–4.22 (m, 2 H, H–C–OPh), 4.11–3.44 (dPG 
– backbone), 3.32–3.28 (m, 2 H, H–C–NH), 2.91–2.85 (m, 1 H, H– ring), 2.85–2.80 (m, 1 H, 
H–ring), 2.03–1.94 (m, 2 H, H–ring), 1.90–1.82 (m, 1 H, H– ring), 1.42–1.14 (m, 2 H, H–
aliphatic) ppm. 
13C–NMR (176 MHz, CD3OD): δ = 161.4, 161.2, 159.2, 138.6, 138.0, 137.4, 133.3, 129.6, 
129.3, 115.4, 105.6, 104.9, 81.4, 80.2, 79.9, 76.6, 74.1, 74.0, 73.0, 73.0, 72.6, 72.5, 72.4, 72.2, 
71.0, 70.8, 69.2, 68.6, 66.7, 64.5, 64.4, 62.8, 50.4, 45.9, 45.1, 43.5, 42.8, 39.5, 38.9, 30.8, 30.4, 
29.9 ppm. 48 
IR (ATR): ν̃ = 3374, 2871, 1696, 1614, 1517, 1458, 1394, 1327, 1304, 1244, 1075, 977 cm-1. 
EA (C847H1475N13O440): calc. C (53.88%), found C (53.29%); calc. N (0.96%), found N 
(1.94%); calc. H (7.87%), found (8.21%).
dPG-THP-norbonene5% (MM6)
DMF (10 mL), dPG-THP-NH2 (440 mg, 0.3 mmol NH2), NEt3 (170 µL, 3 eq), BCN (132 mg, 
0.42 mmol) in DMF (3 mL). The product was stored as the methanolic solution in the freezer 
(5%, 91%).
1H–NMR (700 MHz, CD3OD): δ = 6.23–6.02 (m, 2 H, H-olefin), 3.95–3.54 (m, dPG–
backbone, 2.94–0.61 (m, 6 H, aliphatic-H).































































13C–NMR (176 MHz, CD3OD): δ = 159.23, 138.54, 133.31, 98.72, 81.64, 81.43, 80.16, 79.89, 
73.99, 72.96, 72.46, 72.23, 70.98, 70.68, 69.33, 64.42, 62.83, 50.37, 49.85, 45.12, 43.49, 42.86, 
39.79, 39.50, 30.62, 29.88, 29.06, 24.55, 18.79.
dPG-THP-BCN5% (MM7)
DMF (10 mL), dPG-THP-NH2 (440 mg, 0.3 mmol NH2), NEt3 (170 µL, 3 eq), BCN (144 mg, 
0.45 mmol) in DMF (3 mL). The product was stored as the methanolic solution in the freezer 
(5%, quantitative).
1H–NMR (700 MHz, CD3OD): δ = 3.96–3.55 (m, dPG–backbone), 2.44–0.73 (m, 11 H, 
aliphatic-H-BCN).
13C–NMR (176 MHz, CD3OD): δ = 157.96, 98.28, 80.25, 80.04, 78.82, 78.51, 72.62, 71.58, 
71.07, 70.84, 69.61, 69.30, 67.87, 63.11, 63.03, 61.43, 48.46, 33.07, 28.85, 28.04, 23.72, 22.84, 
20.63, 20.05, 17.62, 17.40.
2.4 Inverse Nanoprecipitation of Macromonomers
General Procedure: The ratio of macromonomer A (dPG-metTet) to macromonomer B (dPG-
dienophile) was set to 1:1.5. Acetone was used as the non-solvent. Parameters, such as solvent 
to non-solvent ratio (1:20 – 1:80) and water quenching time Tq, water (0 – 120 min) were varied 
according to the tables described in the results and discussion section. As an example, a general 
procedure for one set of parameters is described in detail below.
Macromonomers A and B were stored as stock-solutions of 100 to 150 mg mL-1 in water. 
Aliquots were taken and separately diluted with water to a final volume of 1 mL. For this, 15 µL 
of macromonomer A were diluted with 485 µL water and 22.5 µL of macromonomer B with 
477.5 µL water. Both solutions were cooled in an ice bath to 4 °C. Macromonomer A solution 
was added fast to solution B and vortexed for 5 seconds. Then, the solution was added fast via 































































syringe to a 60 mL glass vial containing magnetically stirred acetone (40 mL) at 1200 rpm. The 
turbid dispersion was stirred for another 2 seconds and then kept still for 10 min. The reaction 
was then quenched by the addition of 20 µL of 2-(vinyloxy)ethan-1-ol. Water (1/3 of acetone) 
was added after 30 min and the acetone was removed under reduced pressure. Purification was 
performed by centrifugal filtration, using a membrane with a cutoff of 1 MDa and 3 consecutive 
washing steps with 10 mL distilled water/PBS buffer each. Nanogels were obtained as stable 
dispersions in water and characterized using DLS, NTA, and Zeta-potential measurements. 
2.5 Coprecipitation of Asparaginase
The inverse nanoprecipitation was performed as described in Section 2.4. 225 µL of a 
1.11 mg/mL stock solution of asparaginase were added to the dPG-metTet macromonomer 
solution and thoroughly mixed. The total volume of water was kept at 1 mL. 5 wt.% of 
asparaginase were encapsulated each for dPG-norbonene-, dPG-BA-norbonene and dPG-THP-
norbonene-NGs (n = 3). The gels were purified by centrifugation filtration, using filters with a 
molecular weight cut-off of 1 MDa at 234 rcf. The gel volume was reduced to 1 mL and fresh 
PBS buffer was added (10 mL). Then the volume was reduced to 1 mL again and the whole 
process was repeated three times to ensure the complete removal of the non-encapsulated 
protein.
2.6 Protein Content Determination Assay
A standard Pierce BCA assay kit was used for the determination of asparaginase content within 
the nanogels. 25 µL of the purified nanogels were added to a 96-well plate. Then 200 µL of 
working reagent was added to each well and the plate was shaken for 30 seconds on a plate 































































shaker. The plate was then incubated at 37 °C for 1 h. After cooling to room temperature, the 
absorbance was measured at 562 nm on a plate reader. Samples were recorded in triplicates and 
for three independent gels of the same type. Calibration curves were prepared for a dilution 
series of albumin and asparaginase in the range of 0 to 1000 µg mL-1. Concentrations of 
asparaginase in the samples were determined via the fitted standard curves of asparaginase 
(Figure S4).
2.7 Degradation of Nanogels
For the continuous degradation experiments, 100 µL of 2 mg/mL were diluted with buffer to 
200 µL total volume. For each pH value a different buffer was used. In case of pH 7.4, a 10 mM 
PBS buffer, in case of pH 4.5 10 mM acetate buffer and in case of pH 3 the same acetate buffer 
with addition of 1M HCl were used. 
The solutions were placed in a disposable UV-cuvette and measured continuously with a 
Malvern zeta- sizer nano ZS 90 with He–Ne laser (λ = 532 nm) at 173° backscatter and 
automated attenuation at 25 °C for 16 h.
For nanogels with protein content 333 µL of 1.1 mg/mL nanogel dispersion were diluted with 
500 µL of the buffer solutions and agitated continuously with a vortex at lowest agitation speed 
for 48 h. At 30 min, 1 h, 3 h, 5 h, 8 h, 24 h, and 48 h a sample of 70 µL was taken for each pH 
value, snap frozen in liquid nitrogen and stored at -20 °C in the freezer. Particle size 
distributions were measured for each time point and pH value using a Malvern zeta- sizer nano 
ZS 90 with He–Ne laser (λ = 532 nm) at 173° backscatter and automated attenuation at 25 °C. 
A mean of three measurements is reported.































































2.8 Cell Viability Assay
Cell viability was determined using a CCK-8 Kit (Sigma-Aldrich) according to the 
manufacturer’s instructions. A549, HeLa and MCF-7 cells were obtained from Leibniz-Institut 
DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH and cultured in 
DMEM (A549 cells) or RPMI 1640 (HeLa and MCF-7 cells) supplemented with 10% (v/v) 
FBS, 100 U/mL penicillin and 100 μg mL-1 streptomycin.
A549, HeLa and MCF-7 cells were seeded in a 96-well plate at a density of 5 x 104 cells/mL in 
90µl DMEM/RPMI Medium per well over night at 37°C and 5% CO2. 10 µL of dPG-metTet or 
dPG-dienophile (solved in deionized water) were added in serial dilutions including positive 
(1% and 0,1% SDS) and negative controls (cell culture medium and 10% H2O in cell culture 
medium) and incubated for another 24 h at 37°C and 5% CO2.
For background subtraction, also wells containing no cells but only sample were used. After 
24h incubation the CCK8 solution was added (10 µL/well) and absorbance (450nm/650nm) 
was measured after approximately 3 h incubation of the dye using a Tecan plate reader (Infinite 
pro200, TECAN-reader Tecan Group Ltd.).
Measurements were performed in triplicates and repeated three times. The cell viability was 
calculated by setting the non-treated control to 100% and the non-cell control to 0% after 
subtracting the background signal using the Excel software.































































3. Results and Discussion
3.1 Synthesis of Precursors and Macromonomers
The synthetic accessibility of macromonomers and precursors for nanogel formation is quite 
important, as any useful application needs scalable and high yielding reactions. For the inverse 
nanoprecipitation itself a highly efficient and bioorthogonal crosslinking chemistry is needed. 
The iEDDA crosslinking chemistry we used, provides the efficient and fast reaction to produce 
nanogels in a reliable fashion. The synthetic focus of this work thus lies on the synthetic 
description of the pH-cleavable THP linker that was used, to our knowledge, for the first time 
and the different macromonomers that were obtained from the dPG-benzacetal- and dPG-THP-
amine cores. 
The second most important property for a biological application is the biocompatibility 
of the synthetic polymers that are used. Dendritic polyglycerol is a platform for straightforward 
post-modification and has already been shown to be biocompatible.[54] The polymer itself can 
be obtained on a multigram to kilogram scale and is easy to functionalize either directly via the 
hydroxyl groups or by a short reaction sequence that leads to the dPG-amine derivative. This 
dPG-amine can then be reacted with a large variety of molecules to further introduce 
functionality to the polymer. In this way many different non-degradable macromonomers for 
iEDDA can be generated in a straightforward and scalable fashion. 
The synthetic routes for the activated carbonates of the dienophiles (1 + 2), the methyl 
tetrazine carboxylic acid (3), the benzacetal-azide precursor (4) and the DHP-azide (5) can be 
found in Scheme S1 in the Supporting information. These precursors were then used to 
functionalize dPG, as well as dPG-amine to the corresponding macromonomers that were used 
in this work. The synthetic routes are described in Scheme 1.































































Scheme 1 Synthetic overview for the different macromonomers. The following conditions were used: (a) MsCl, 
NEt3, DMF, rt, overnight, (b) NaN3, 60 °C, 3 d, (c) PPh3, water/THF, rt, 3 d, (d) 1, NEt3, DMF, rt, overnight, (e) 
2, NEt3, DMF, rt, overnight, (f) 5, HATU, DIPEA, DMF, rt, overnight, (g) 1-(3-azidopropoxy)-4-
(dimethoxymethyl)benzene, pTSA, DMF, 40°C, overnight and (h) 3, pTSA, DMF, rt, overnight. Number of 
reactive groups not representative; just for clearness
Norbonene was chosen as the reactive dienophile because its activated carbonate form can be 
obtained in a high yielding two step reaction from the commercially available and quite 
inexpensive precursor bicyclo[2.2.1]hept-5-ene-2-carbaldehyde. The methyl tetrazine 
carboxylic acid (3) has also been shown to be easily attached to the dPG-amine core via simple 
amide bond formation and the corresponding macromonomer is stable for extended periods of 
time in MeOH and water.
BCN was used as a comparison to norbonene, as it can be obtained from commercial sources, 
although the price is quite high, and the synthetic route is low yielding and lengthy.[55] It is 
most commonly used in SPAAC click reactions in combination with organic azides, however 
it has some cross-reactivity with thiols, limiting its biorthogonality. 































































In order to introduce pH-degradability to the system, we chose two different types of 
acetal linkers between the dPG core and the dienophiles. The benzacetal (BA) linker (4) is 
known to degrade at pH values below 5 and the cyclic aliphatic acetal that is generated in 
macromonomers 6 and 7 can degrade at pH values below 3. Synthetically, the BA precursor 
was obtained in 4 steps and was directly attached to the dPG core by trans-acetalization of the 
terminal 1,3 diols of the polymer to form the cyclic aromatic acetal motif that can be seen in 
Scheme 1. The precursor for the aliphatic acetal linking groups can be obtained by modification 
of a common protecting group for alcohols in organic synthesis, the DHP protecting group. A 
slightly modified precursor is commercially available ((3,4-dihydro-2H-pyran-2-yl)methanol). 
This was transformed in two steps to the corresponding DHP-azide (5) which was then attached 
to the dPG-core by an acid catalyzed addition reaction.
The polymer azides that were obtained in this fashion were then reduced to the 
corresponding amines, using a Staudinger reduction. The dPG-acetal amines are the platform 
for the attachment of the activated carbonate forms of the dienophiles. These dPG-acetal-
dienophiles (MM 4 - MM7) were obtained in high yields of 85 to >99% applying the same 
synthetic method for each macromonomer. This toolbox of monomers was then characterized 
using NMR, IR, and DLS. The degradable macromonomers were then employed to produce 
nanogels via inverse nanoprecipitation in acetone. 
3.1 Nanogel Preparation by Inverse Nanoprecipitation
In general, the inverse nanoprecipitation method works by injection of a solution of 
macromonomers in a suitable solvent, such as water, into the corresponding non-solvent of said 
macromonomers, in this case acetone. While the water is dispersed within the acetone, the 































































insoluble macromonomers precipitate out of solution. First small aggregates are formed which, 
with time, form larger and larger conglomerates. Due to the local concentration of these 
macromonomers within the aggregates being high, the reaction of the dienophiles with methyl 
tetrazin proceeds very fast and thus leads to the crosslinking of the aggregates to form a 
hydrohilic nanogel network. As time proceeds, the small gel networks come into contact and 
crosslink further until almost all macromonomers are consumed, yielding the stable dispersions 
of nanogels acetone. By the addition of water, the gel formation is quenched and upon removal 
of acetone the nanogels are obtained as stable dispersions in water. The simplified process can 
be seen in Scheme 2 with dPG-BA-norbonene and dPG-metTet as an example.
Scheme 2 Simplified overview on the inverse nanoprecipitation process, pH decrease leads to 
disintegration of the network and the release of the protein cargo
We studied the parameters that have the most influence on nanogel formation with this 
type of macromonomers. It was observed that the time when water is added to the reaction 
mixture and the water/acetone ratio are the most influential parameters on nanogel size.































































As can be seen in Table 1 and Table 2 we investigated the influence of water to acetone ratios 
on nanogel size and polydispersity for dPG-BA-norbonene and dPG-BA-BCN nanogels, 
respectively. 











1 1:1.5 5 1:80a 102 ± 2 0.03 ± 0.01
2 1:1.5 5 1:60 120 ± 2 0.02 ± 0.01
3 1:1.5 5 1:40 91 ± 1 0.04 ± 0.02
4 1:1.5 5 1:20 62 ± 1 0.08 ± 0.01
A = dPG-metTet; B = dPG-BA-norbonene, a = different container used for gelation compared to other 
water/acetone ratios, Tq, chem = 10 min, Tq, water = 30 min











1 1:1.5 5 1:80a 94 ± 1 0.06 ± 0.01
2 1:1.5 5 1:60 147 ± 2 0.10 ± 0.01
3 1:1.5 5 1:40 88 ± 1 0.07 ± 0.01
4 1:1.5 5 1:20 47 ± 1 0.10 ± 0.01
A = dPG-metTet; B = dPG-BA-BCN, a = different container used for gelation compared to other water/acetone 
ratios, Tq, chem = 10 min, Tq, water = 30 min
The overall trend is summarized in Figure 1.































































Figure 1 Size trend and polydispersity of nanogels formed from MM 4 and MM5 with varying water to acetone 
ratio during inverse nanoprecipitation
It is evident that there is a trend towards smaller nanogels when the ratio of water to acetone 
becomes bigger. This is expected, as a higher water content increases the solubility of the 
macromonomers in the mixture of water and acetone, thus leading to smaller aggregates in the 
non-solvent. The ratio of 1:80, however, is an outlier since the glass vial that was used for the 
experiments had a maximum volume of 60 mL. Therefore, this ratio was performed in a 
different glass container which influenced the nanogel formation. This trend is observed for 
both macromonomers indicating that the geometry of the container has an impact on gel size. 
Moreover, the polydispersity of the final nanogels in water is not significantly 
influenced by the high ratios of water:acetone which offers the opportunity to produce small 
nanogels without a negative impact on the polydispersity of the gels and using relatively low 
amounts of organic solvent, which simplifies the overall process of nanogel production.































































The second most influencing parameter we tested was the time when water was added 
to the mixture in order to stop any further crosslinking between already formed nanoaggregates. 
The results for a variety of quenching times between 4 and 60 min is shown for dPG-BA-
norbonene/dPG-metTet in Table 3.











1 1:1.5 5 60 88 ± 1 0.04 ± 0.01
2 1:1.5 5 30 92 ± 1 0.04 ± 0.01
3 1:1.5 5 10 75 ± 1 0.20 ± 0.01
4 1:1.5 5 5 nd nd
5 1:1.5 5 4 nd nd
A = dPG-metTet; B = dPG-BA-norbonene, nd = measurement quality criteria not achieved due to very high 
polydispersity, V(H2O):V(acetone) = 1:40, Tq, chem = 10 min
One can see that immediate quenching after four- or five-minutes leads to a complete disruption 
of nanogel formation as the resulting gel/macromonomer mixtures were so polydisperse that 
they did not reach the measurement quality to report a reliable value. After ten minutes the gel 
seemed to have formed, however, the polydispersity was quite high compared to other batches, 
which indicates that at this timepoint there is still unreacted small aggregates present. After 
around 30 min the gel is fully formed and no significant change in nanogel size can be observed. 
The polydispersity, however, reaches very good values of below 0.05.































































We decided to test only larger quenching times for MM5 as it was evident that a real 
control over nanogel size using small quenching times was not possible. The results for 
quenching times between 30 and 60 min are summarized in Table 4.











1 1:1.5 5 30 73 ± 1 0.08 ± 0.01
2 1:1.5 5 40 65 ± 1 0.07 ± 0.01
3 1:1.5 5 50 62 ± 1 0.10 ± 0.01
4 1:1.5 5 60 72 ± 1 0.07 ± 0.01
A = dPG-metTet; B = dPG-BA-BCN, V(H2O):V(acetone) = 1:40, Tq, chem = 10 min
As expected, the longer quenching times did not have an influence on nanogel size as most of 
the crosslinking happened in the first few minutes. However, it also showed that most of the 
reactive surface groups were consumed within the first hour, which prevented bigger aggregates 
and possibly complete precipitation of the nanogels. PDI values were also not significantly 
affected using these quenching times and stayed between 0.07 and 0.1.
The nanogels were obtained in a reproducible manner. We thus chose the norbonene 
derivative to perform co-precipitation of the therapeutic protein asparaginase. 































































3.2 Asparaginase Encapsulation by Coprecipitation
The protein asparaginase is used as a drug to treat acute lymphoblastic leukaemia (ALL). A 
PEGylated version is available on the market (Oncaspar®)[3].
5 wt.% of protein compared to the total amount of macromonomers were chosen for 
encapsulation, without severely impacting the polydispersity of the gels. However, the size of 
the nanogels almost always increased to higher values when compared to gels that were 
produced without the addition of a protein.
The norbonene derivatives of the macromonomers (MM1, MM4, MM6) were used to 
perform the coprecipitation of asparaginase, as the precursors are synthetically more accessible 
compared to the BCN derivatives and should have negligible reactivity towards biological 
systems. As a control we used nanogels that were prepared without the addition of asparaginase 
during nanoprecipitation. The results are summarized in Figure 2.































































Figure 2 Co-precipitation of asparaginase at 5 wt.% feed with MM1/MM3, MM4/MM3, and MM6/MM3. (A) 
DLS data for a gel without (black) and with asparaginase (red) present during gel formation (dPG-norbonene-NG), 
(B) DLS data for a gel without (black) and with asparaginase (red) present during gel formation (dPG-BA-
norbonene-NG), (C) DLS data for a gel without (black) and with asparaginase (red) present during gel formation 
(dPG-THP-norbonene-NG), (D) encapsulation efficiency determined by a BCA assay for gels with asparaginase 
and control gels without; the readout of the control gels was subtracted from the values that were determined for 
the gels containing asparaginase
It is evident, that the coprecipitation of a protein influenced the size of the resulting 
nanogels to higher values. We hypothesize that this was due to interactions of the protein with 
the macromonomers during the inverse nanoprecipitation process which lead to the formation 
of bigger initial aggregates which grew faster during the gel formation process, thus resulting 
in bigger nanogels. 































































After a purification process, where the gels were washed in a centrifugal filter with PBS, 
most of any free protein should be removed from the gel dispersions. The gels were then tested 
regarding their protein content, using a standard BCA assay with a dilution series of free 
asparaginase as the standard curve (Figure S4). Gels that were formed without the addition of 
asparaginase were used as a control and the OD values for these gels were subtracted from the 
gels that contained asparaginase. The results of the encapsulation efficiency can be seen in 
Figure 2 D. All three types of gels, namely dPG-norbonene, dPG-BA-norbonene-, and dPG-
THP-norbonene nanogels reached very good encapsulation efficiencies of between 81 and 93%, 
showing the suitability of these macromonomers to form gels that efficiently entrap 
asparaginase within their gel network. 
The pH-degradability of the different types of acetal functionalized nanogels was then 
tested at different pH-values.
3.3 pH-Triggered Degradation of Nanogels
In order to study the degradation behavior of the gels we added the different types of gels which 
contained asparaginase to buffer at different pH values. Every group of gel was exposed to pH 
7.4, pH 4.5, and pH 3 at moderate agitation and room temperature. The degradation was then 
followed over the course of 48 h. At each time point a sample was taken and snap frozen in 
liquid nitrogen to be later measured by DLS. The results are shown in Figure 3 and Figure S8.































































Figure 3 Degradation profiles of dPG-BA-norbonene- and dPG-THP-norbonene at pH 7.4, pH 4.5 and pH 3. (A)- 
(C) dPG-BA-norbonene-NG at pH 7.4, 4.5, and 3. (D)- (F) dPG-THP-NG at pH 7.4, 4.5, and 3
At pH 7.4 (A + D) both gels do not show degradation at all. Through the strong agitation, 
however, the particles tend to aggregate and show a strong increase in polydispersity. In terms 
of degradation, there was no significant amount of small particles observable. However, at pH 
4.5 nanogel degradation was observed for the gel with BA linking groups (B). At first, swelling 
of the nanogels was observed, which shifted the distribution towards bigger size values, while 
only after 24 h small particles appeared at around 20 nm in a mix with still intact nanogels. 
After 48 h, however, most particles were in the size range of around 20 nm. In contrast, even 
after 48 h no degradation was observed for the aliphatic THP-acetal linker containing gel (E). 
This was expected, as these kinds of acetals degrade usually only at pH values of below 3. 
At pH 3, the dPG-BA-norbonene NG (C)degraded much faster than at pH 4.5. After already 
3 h particles of around 50 nm were observed and after 8 h mostly particles of around 20 nm 
remained. At 48 h nearly all particles were degraded to around 10 nm, which signaled the 
complete breakdown of the gels into mostly macromonomers.































































The dPG-THP-norbonene-NG at pH 3 in contrast to pH 4.5, started to degrade and showed 
smaller particles of around 50 nm after 8 h. After 48 h almost complete degradation to particles 
of around 20 nm was observed. 
In order to see a more detailed degradation profile of the dPG-BA-norbonene-NGs a 
continuous monitoring over the course of 18 h was performed. For this, a nanogel without 
protein was degraded in acetate buffer at pH 4.5 within a DLS cuvette and measured 
continuously while every measurement corresponds to roughly 2 min. The results are shown in 
Figure 4.
Figure 4 Continuous degradation profile of dPG-BA-norbonene-NG at pH 4.5 in acetate buffer. Size by volume, 
Z-Average, size by number and PDI are shown. The derived count rate is shown for comparison
The black curve in every diagram corresponds to the derived count rate. This was constantly 
decreasing over time, which indicated less, and less particle counts over time. However, over a 
long period of time of around 8 to 9 h not much change could be observed in the volume and 
number distributions. If at all, there is a slight increase in size, probably due to swelling of the 































































gels. After around 9 h, the PDI value slowly started to rise, which showed that a mixture of 
particles must be present with a wider distribution of sizes. This could also be observed in the 
size by volume and number distributions. From this point on, the size values continued to 
decrease until at around 13 h the count rate became too low for the measurement quality to 
obtain reliable results. This was indicated by the fluctuation of measurement values and the 
strong spreading of the distribution of values. However, at least a trend could be observed, 
which showed that the gels disintegrated between 9 h and 14 h to values below 20 nm. 
All in all, this shows that the gels based on the BA linkers that were used can be degraded 
at pH values that can be found in endosomes and lysosomes. At pH 7.4 all gels were stable for 
extended periods of time, as can be seen in Figure S6. NTA measurements of the same gels 
also confirmed, that the particle sizes obtained from DLS are comparable (Figure S7).
3.4 CCK8 Cell Viability Test
For any application handling living cells or in vivo experiments, it is necessary to know if the 
macromonomers that are used are non-toxic to the cells at reasonable concentrations. In the 
case of the nanogels we presented here, no free macromonomers remain, however for 
applications such as microgelation and co-encapsulation of living cells it is absolutely 
mandatory to see if the macromonomers are toxic, because they come into direct contact with 
the cells they encapsulate. After gel formation the gels are mostly appearing as hydrophilic 
networks, presenting a lot of hydroxyl groups and it has been demonstrated before that 
nanogels, based on dPG do not impact the cell viability negatively within a certain 
concentration range.[56] 
The results for three different cell lines are summarized in Figure 5.































































Figure 5 Cell viability assay of all different macromonomers using three different cell lines, A) A549 cell line, B) 
HeLa cell line, C) McF7 cell line.
All macromonomers did not have a big impact on cell viability up to approximately a 
concentration of 156 µg mL-1, however, dPG-THP-norbonene exhibited slight cytotoxicity at 
concentrations higher than this. The rest of the macromonomers were non-toxic even up to 
concentrations of 2.5 mg mL-1. This indicated that the macromonomers are suitable even for 
applications with living cells.
Conclusion
We have shown the synthesis of different reactive macromonomers for iEDDA click chemistry 
mediated production of pH-degradable nanogels that are degraded at their acetal linking points. 
Three different groups of nanogels were produced. Non-degradable gels, degradable gels, based 































































on an aromatic BA linker, and degradable gels based on an aliphatic THP acetal were obtained. 
The NGs were synthesized in the size range of 47 -200 nm with excellent polydispersity indices 
of 0.1 and below.
Co-precipitation of the therapeutic protein asparaginase showed excellent encapsulation 
efficiencies of between 81 and 93% for nanogels made from dPG-norbonene and dPG-BA-
norbonene, respectively. 
Gels based on the aromatic BA linker, were degraded at pH values of 4.5, within 24 h, 
while THP-linked gels were not degraded at all at this pH. dPG-BA-norbonene gels were 
degraded fast within 9 h at pH 3 and dPG-THP gels showed complete degradation within 24 h 
at this pH showing the applicability of the dPG-BA-dienophile gels for degradation within 
endosomal to lysosomal pH windows. All gels were stable in PBS at pH 7.4 for extended 
periods of time. The macromonomers used, did not show cell toxic effects up to about 2.5 mg 
mL-1, except for dPG-THP-norbonene. 
The low toxicity of the macromonomers, as well as the reproducible gel formation 
within a reasonable size range and low polydispersity, together with the excellent encapsulation 
efficiency, make the nanogels ideal for the delivery of therapeutic proteins. As a future 
perspective, functionalization of the dPG-core with targeting ligands could be performed, in 
order to obtain nanocarriers that have active-, as well as passive targeting properties.
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Materials and Analytical Methods
Ethyl acetate, n-pentane and diethyl ether were obtained from the technically pure solvents by 
distillation before use. Dry DCM and THF were used from a SPS-800 type MBRAUN solvent 
drying system. Acetone and DCM (HPLC grade) were used without further purification. Dry 
methanol and DMF were purchased from Acros and Fischer Chemical. All other chemicals and 
deuterated solvents were obtained from Sigma Aldrich, Acros, Merck, and Fisher Chemicals 
and were used as without further purification. Thin layer chromatography (TLC) was performed 
on silica gel-coated aluminum plates, serving as stationary phase (silica gel 60 F254 from 
Macherey-Nagel). Identification of analytes was done by UV-irradiation (λ = 254 nm) of the 
TLC plates or by treatment with a potassium permanganate-based (100 mL deionized water, 
200 mg potassium permanganate) or anis aldehyde-based staining solution (450 mL EtOH, 25 
mL anis aldehyde, 25 mL conc. sulfuric acid, 8.0 mL acetic acid). Column chromatography was 
performed with silica gel (Macherey-Nagel, grain size 40 - 63 μm, 230 - 400 mesh) as stationary 
phase and the indicated eluent mixtures as the mobile phase.































































IR spectra were recorded on a JASCO FT/IR-4100 spectrometer. The characteristic absorption bands 
are given in wave numbers. 1H NMR spectra were recorded at 300 K on Joel ECX 400 400 MHz and 
AVANCE III (700 MHz) instruments. Chemical shifts δ are indicated in parts per million (ppm) relative 
to tetramethyl silane (0 ppm) and calibrated as an internal standard to the signal of the incompletely 
deuterated solvent (CDCl3: δ = 7.26 ppm, MeOD: δ = 3.31 ppm). Coupling constants J are given in 
Hertz (Hz). 13C NMR spectra were recorded at 300 K on AVANCE III instruments (176 MHz). Chemical 
shifts δ are given in ppm relative to tetramethyl silane (0 ppm) and calibrated as an internal standard to 
the signal of the incompletely deuterated solvent (CDCl3: δ = 77.16 ppm, MeOD: δ = 49 ppm). Coupling 
constants J are given in Hertz (Hz). The spectra are decoupled from proton broadband. DLS and Zeta 
potential were measured on a Malvern zeta- sizer nano ZS 90 with He–Ne laser (λ = 532 nm) at 173° 
backscatter and automated attenuation at 25 °C. Three measurements were performed per sample, 
yielding a mean size value plus standard deviation. Sample concentration was kept at 1 mg mL-1. GPC 
was performed on an Agilent 1100 at 5 mg mL-1 using a pullulan standard, 0.1 M NaNO3 solution as 
eluent and a PSS Suprema column 10 μm with a flow rate of 1 mL min-1. Signals were detected with an 
RI detector.
Precursor Synthesis
Activated carbonate precursors of the different dienophiles were partially synthesized 
according to literature-known procedures. Some procedures were modified as indicated. 





























































































Scheme S1 Synthetic overview of the precursor molecules. (a) Rh-acetate dimer, ethyl diazoacetate, DCM; (b) 
LiAlH4, THF; (c) Br2, DCM; (d) KOtBu, THF; (e) 4-nitrophenyl chloroformate, py, DCM; (f) acetamidine 
hydrochloride, hydrazine, Zn(OTf)2, then NaNO2, HCl; (g) NaN3, NBut4 HSO4, H2O, 80 °C, overnight; (h) 3-
azidopropanol, TsCl, NEt3, DCM, 0 °C to rt, overnight; (i) 4-hydroxybenzaldehyde, 3-azidopropyl 4-
toluenesulfonate, K2CO3, acetone, reflux, overnight, (j) 4-(3-azidopropoxy) benzaldehyde, trimethyl orthoformate, 
pTSA, MeOH, reflux, 24 h, (k) MsCl, NEt3, DMF, 0 °C to rt, overnight and (l) NaN3, DMF, 80 °C, 2 days
BCN (1) was synthesized according to literature procedure.[1]
dPG-BCN (MM2) was synthesized according to literature protocol.[2]
dPG-norbonene was synthesized according to literature protocol.
4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzoic acid (3) was synthesized according to a modified 
literature protocol:[3]
4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzoic acid
4-cyanobenzoic acid (1.5 g, 10 mmol), acetamidine hydrochloride (4.82 g, 41 mmol) and 
Zn(OTf)2 (1 g, 3 mmol) were ground in a mortar, added to a 100 mL Schlenk flask under argon 
atmosphere and cooled to 0 °C. Anhydrous hydrazine (12 mL, 377 mmol) was then slowly 
added under constant stirring, the reaction mixture was allowed to warm to room temperature 































































and stirred for 72 h. NaNO2 (10 g) dissolved in 30 mL of water was then added to the reaction 
mixture. After cooling to 0 °C, the pH was adjusted to 2-3 by the slow addition of conc. HClaq. 
The color of the solution turned bright pink and a pink solid precipitated. After stirring at 0°C 
for another 1 h, the precipitate was filtered and washed with deionized water and MeOH. The 
product was obtained as a pink solid without further purification (1.1 g, 50 %).
1H-NMR (400 MHz, DMF-d7): δ = 13.80 (s, 1 H, COOH), 8.67 – 8.65 (m, 2 H, ArH), 8.32 – 
8.29 (m, 2 H, ArH), 3.09 (s, 3 H, -CH3) ppm.
13C-NMR (101 MHz, DMF-d7): δ = 168.95, 167.92, 137.23, 135.51, 131.41, 128.72, 21.63 
ppm.
Polymer Core
dPG and dPG-amine were synthesized according to literature protocols.[4, 5]
Figure S1: GPC-analysis of the dPG-core.
































































dPG-BA-azide8% was synthesized according to a modified literature protocol[6]:
dPG-BA-azide8%
dPG (4.16 g, 55.39 mmol) was dried at the HV at 70 °C overnight and dissolved in dry DMF 
(50 mL). The benzacetal (4) (1.48 g, 5.76 mmol) was dissolved in dry DMF (50 mL) and added 
to the dPG – solution via syringe and p-TSA (0.04 g, 0.22 mmol) was added. The resulting 
solution was stirred at 40 °C and MeOH was continuously removed through distillation. The 
crude product was constricted under reduced pressure and dialyzed against water and methanol 
1:1 for four days and methanol for nine days (MWCO = 1 kDa). The product was obtained as 
methanolic solution (8 % functionalization, 85 %). 
1H–NMR (700 MHz, CD3OD): δ = 7.48–7.40 (m, 2 H, H–aromatic), 7.00–6.93 (m, 2 H, H–
aromatic), 5.90–5.87 (m, 1 H, H–acetal), 4.49–4.34 (m, 2 H, H–C–N3), 4.10–3.46 (m, dPG – 
backbone), 2.09–2.01 (m, 2 H, H–aliphatic) ppm. 
13C–NMR (176 MHz, CD3OD): δ = 129.6, 115.4, 105.6, 104.9, 79.9, 74.0, 73.0, 72.3, 66.0, 
64.4, 29.9 ppm. 
IR (ATR): ν = 3350, 2913, 2876, 2361, 2342, 2098, 1653, 1245, 1070, 1024 cm-1. 
EA (C80H140N6O43): calc. C (51.27%), found C (49.46%); calc. N (4.48%), found N (5.78%), 
calc. H (7.53%), found H (8.47%).
dPG-BA-amine10% was synthesized according to a modified literature protocol[6]:
































































The solvent of the dPG–benzacetal-azide (2.00 g, 26.62 mmol, 14.40 mL) solution was removed 
under reduced pressure. THF (70 mL), water (80 mL) and PPh3 (3.50 g, 13.33 mmol) was added 
and the solution was stirred for seven days at room temperature. THF was removed under 
reduced pressure and the crude product was filtered. The filtrate was constricted under reduced 
pressure. The crude product was dialyzed against methanol for (MWCO = 1 kDa) for 3 days. 
The product was obtained as a methanolic solution (8.5% functionalization, 93%). 
1H–NMR (700 MHz, CD3OD): δ = 7.47–7.39 (m, 2 H, H–aromatic), 7.01–6.92 (m, 2 H, H–
aromatic), 5.89–5.71 (m, 1 H, H–acetal), 4.46–4.35 (m, 1 H, H–C–O), 4.13–3.46 (dPG – 
backbone), 2.97–2.88 (m, 1 H, H–C–NH2), 2.06–1.95 (m, 1 H, H–aliphatic) ppm. 
13C–NMR (176 MHz, CD3OD): δ = 129.6, 129.3, 115.3, 105.6, 104.9, 81.5, 81.4, 80.2, 79.8, 
76.6, 74.1, 74.0, 73.0, 72.5, 72.2, 71.1, 70.7, 68.5, 67.0, 67.0, 64.4, 62.9, 39.5, 32.2 ppm. 
IR (ATR): ν̃ = 3360, 2827, 2360, 2341, 1613, 1589, 1516, 1457, 1438, 1392, 1116, 1069 cm-
1.
dPG-BA-BCN6.5% was synthesized according to a modified literature protocol[6]:
dPG-BA-BCN6.5%
DMF (14 mL), dPG–BA-amine (10.00 mL, 0.062 g/mL), Et3N (0.16 g, 1,62 mmol, 0.22 mL), 
BCN (0.19 g, 0.59 mmol) in DMF (10 mL). The product was obtained as a yellow methanolic 
solution (6.5% functionalization, 94%). 
1H–NMR (700 MHz, CD3OD): δ = 7.47–7.38 (m, 2 H, H–aromatic), 6.99–6.92 (m, 2 H, H–
aromatic), 5.89–5.72 (m, 1 H, H–acetal), 4.46–4.33 (m, 1 H, H–C–O), 4.30–4.13 (m, 2 H, H–
C–carbamate), 4.13–3.44 (dPG – backbone), 2.40–2.08 (m, 4 H, H–2, H– 2’), 2.02–1.93 (m, 































































ring), 1.66–1.33 (m, 4 H, H–ring), 0.98–0.71 (m, 2 H, H–ring), 0.71– 0.65 (m, 1 H, H–ring) 
ppm. 
13C–NMR (176 MHz, CD3OD): δ = 129.6, 129.3, 115.4, 111.4, 81.6, 79.9, 74.0, 72.2, 70.7, 
64.5, 63.7, 62.8, 34.4, 30.8, 30.2, 25.1, 24.2, 22.0, 21.4 ppm. 
IR (ATR): ν = 3379, 2915, 2873, 1696, 1614, 1517, 1457, 1394, 1304, 1244, 1078, 934 cm-1. 
EA (C873H1501N13O440): calc. C (54.55%), found C (53.11%); calc. N (0.95%), found N 
(1.63%); calc. H (7.87%), found H (7.90%).








dPG-BCN 7.5 12 ± 2 0.30 ± 0.01
dPG-norbonene 9 4 ± 1 0.80 ± 0.02
dPG-metTet 6.5 160 ± 140 0.50 ± 0.01
dPG-BA-BCN 8 3 ± 1 0.75 ± 0.01
dPG-BA-norbonene 8 3 ± 1 0.75 ± 0.04
dPG-THP-BCN 5 9 ± 4 0.30 ± 0.04
dPG-THP-norbonene 5 5 ± 1 0.40 ± 0.04 































































Figure S2 IR-spectra of the different macromonomers 















































































1 1:1.5 5 1:40 10 60 105 ± 2 0.09 ± 0.01
2 1:1.5 5 1:40 10 60 115 ± 1 0.07 ± 0.01
3 1:1.5 7.5 1:40 10 60 112 ± 1 0.07 ± 0.01
4 1:1.5 7.5 1:40 10 60 120 ± 1 0.09 ± 0.01
Asparaginase Encapsulation


















c (BSA) in µg/mL
Figure S3 Standard curve of BSA in BCA assay












































































c (Asparaginase) in µg/mL
Figure S4 Standard curve of asparaginase in BCA assay
Figure S5 Zeta-Potential of Nanogels, derived from the different macromonomers































































Figure S6 DLS distribution of nanogels after synthesis and after 3 to 8 months of storage in 10 mM PBS at pH 
7.4 and 4 °C































































Figure S7 NTA measurements of Gels depicted in Figure S5, size values plus SD
Figure S8 Degradation profile for dPG-norbonene-NG at 3 different pH values, size by volume is shown

































































Norbonene-active ester (2) (1H)
































































































































4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzoic acid (5) (1H)
dPG-norbonene (MM1) (1H)
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4. Conclusion and Outlook 
 
Smart and sensitive nanocarriers for the delivery of therapeutic proteins are needed as 
alternatives for covalent modification with the potentially immunogenic PEG. Nanogels as 
water swollen, highly hydrophilic polymer networks are promising candidates for protein 
delivery vehicles. However, scalable production, under sensitive and mild conditions, is still 
an active area of research. Inverse nanoprecipitation, as one of several production methods, 
offers the potential for the mild and non-destructive encapsulation of sensitive proteins. The 
gel networks are preferably formed by crosslinking of biocompatible, hydrophilic, and easily 
obtainable functionalized polymers. A variety of crosslinking chemistries, such as CuAAC, 
Thiol-Michael addition, and SPAAC have been studied for this purpose. Most of these 
chemistries, however, suffer from low biorthogonality, toxic catalysts, or the low synthetic 
accessibility of the precursors. IEDDA has emerged as an alternative for the other click 
chemistries, with fast reaction kinetics, high biorthogonality and easily accessible precursors. 
 The goal of this study was to design nanogels in a way that most of the mentioned 
criteria for a successful nanocarrier system are fulfilled. Nanogels, based on the 
biocompatible, scalable, hydrophilic and easily functionalizable dPG were presented in this 
work. Inverse nanoprecipitation was used as a mild gelation method, that lacks toxic 
surfactants or damaging ultrasound. The bioorthogonal and fast iEDDA click chemistry, 
based on tetrazines and dienophiles, was established for the first time in the use of nanogel 
production.  
The first study focused on the search for suitable dienophiles for the iEDDA 
crosslinking chemistry. Reactivity and scalability were most important. This was achieved by 
screening of different iEDDA-reactive dienophile macromonomers. For this, the four different 
dienophile macromonomers dPG-norbonene, dPG-BCN, dPG-cyclopropene, and dPG-DHP 
were synthesized. As the tetrazine counterpart, the stable but still reactive dPG-metTet was 
obtained. The macromonomers were compared regarding their ability to form macro-and 
nanogels. Gelation times were determined and revealed that only dPG-norbonene and dPG-
cyclopropene were able to form macrogels, while dPG-BCN showed incomplete, and dPG-
DHP no gel formation at all. For nanogel formation, reaction parameters, such as rotation 
speed, macromonomer concentration, quenching times, and solvent to non-solvent ratios were 
screened. Solvent to non-solvent ratio and quenching time were the most influential 
parameters on nanogel size and polydispersity. The nanogels were obtained in the relevant 
size range of 40 to 200 nm and were stable for at least several months in aqueous solution. 





Co-precipitation of the small model protein myoglobin was performed with the most 
promising macromonomer candidates dPG-norbonene and -cyclopropene. Encapsulation 
efficiencies of above 70% were achieved. Thus, it could be shown that a combination of dPG 
as the polymer scaffold, together with easily obtainable iEDDA reactive groups, such as 
norbonene and methyl tetrazine provide the toolbox for the design of a scalable and functional 
nanocarrier for proteins. 
The second study aimed at transferring the gained knowledge on nanogel formation 
parameters, such as quenching time and solvent to non-solvent ratio on a smart, 
environmentally responsive version of the nanogel system. Environmentally responsiveness 
was achieved by the introduction of pH-cleavable acetal groups. One which is cleavable at pH 
values below 5 (benzacetal) and one which cleaves at values below 3 (THP). For this dPG 
was functionalized with the respective acetal linkers and then further functionalized with the 
dienophiles norbonene and BCN from the first study. Norbonene was the most promising 
candidate and BCN was used as a well-established comparison. The macromonomers showed 
no toxicity up to concentrations of 2.5 mg/mL in three different cell lines. Nanogels in the 
size range of 47-200 nm were obtained, which were stable in aqueous solution at pH 7.4 for 
several months, without decomposition or an increase of polydispersity. Upon exposure to 
acidic conditions, the benzacetal-based nanogels cleaved to small particles at pH 4.5 within 48 
h, while the THP acetal-based nanogels cleaved only at pH 3 to small particles after 48 h. This 
proved the applicability of the nanogels for lysosomal cleavage and intracellular delivery for 
benzacetal gels and a potential delivery to the small intestine by the THP acetal functionalized 
gels. Co-precipitation of the therapeutic protein asparaginase led to encapsulation efficiencies 
of up to 93%. The degradability of the gels, the high encapsulation efficiencies, as well as the 
synthetic accessibility and biocompatibility of the macromonomer precursors, point out the 
potential of this nanocarrier platform for biomedical applications. 
 Based on the data that was obtained, the potential of the iEDDA based nanogels is 
evident. However, scalability must be improved at least for the nanogel production itself. 
Continuous flow methods, such as microfluidic based nanoprecipitation could potentially be 
used for the upscaling of the nanogels presented in this work. Furthermore, the addition of 
active targeting ligands to the nanogels or the macromonomers before inverse 
nanoprecipitation would even further increase the applicability of these nanogels for 
biomedical applications. One way of an easily obtainable active targeting moiety would be the 
sulfation of the dPG-macromonomers, which would introduce L-selectin binding affinity into 







Intelligente und responsive Nanocarrier für die Verabreichung therapeutischer Proteine 
werden als Alternativen für die kovalente Modifikation mit dem potenziell immunogenen 
PEG benötigt. In diese Gruppe gehören Nanogele, die als geschwollene, wasserreiche, sehr 
hydrophile Polymernetzwerke vielversprechende Kandidaten für den Transport von 
therapeutischen Proteinen sind. Die skalierbare Produktion unter milden Bedingungen ist 
jedoch nach wie vor ein aktives Forschungsgebiet. Die umgekehrte Nanopräzipitation, als 
eines von mehreren Produktionsverfahren, bietet das Potenzial für die schonende und 
strukturerhaltende Verkapselung empfindlicher Proteine. Bei diesem Verfahren entstehen 
Gel-Netzwerke vorzugsweise durch die Vernetzung von biokompatiblen, hydrophilen und 
leicht herstellbaren funktionalisierten Polymeren. Eine Vielzahl von Klickreaktionen, wie 
CuAAC, Thiol-Michael-Addition und SPAAC, wurden für die Verwendung als 
Quervernetzungsreaktionen untersucht. Die meisten dieser Reaktionen haben jedoch 
verschiedene Nachteile, wie eine geringe Bioorthogonalität, die Verwendung toxischer 
Katalysatoren oder eine geringe synthetische Zugänglichkeit der Vorstufen. IEDDA hat sich 
hingegen als Alternative zu diesen Klickreaktionen herausgestellt, was an einer schnellen 
Reaktionskinetik, einer hohen Bioorthogonalität und leicht zugänglichen Vorstufen liegt. 
 Ziel dieser Arbeit war es, Nanogele so zu gestalten, dass die meisten der oben 
genannten Kriterien für ein erfolgreiches Nanocarrier-System erfüllt werden. Hierzu wurden 
Nanogele, die auf dem biokompatiblen, skalierbaren, hydrophilen und leicht 
funktionalisierbaren dPG basieren, in dieser Arbeit thematisiert. Die umgekehrte 
Nanopräzipitation wurde als milde Geliermethode eingesetzt, welche ohne toxische Tenside 
oder schädlichen Ultraschall auskommt. Diese wurde kombiniert mit der bioorthogonalen und 
schnellen iEDDA-Click-Chemie, wlche auf Tetrazin und Dienophilen basiert. Die 
Kombination dieser Methoden wurde hier zum ersten Mal für die Darstellung von Nanogelen 
etabliert und im Detail studiert.  
Die erste Studie legte den Fokus auf die Suche nach geeigneten Dienophilen für die 
iEDDA-Vernetzungschemie, wobei Reaktivität und Skalierbarkeit im Vordergrund standen. 
Dies wurde durch das Screening verschiedener iEDDA-reaktiver Dienophil-funktionalisierter 
Makromonomere erreicht. Dazu wurden die vier verschiedenen Makromonomere dPG-
Norbonen, dPG-BCN, dPG-Cyclopropen und dPG-DHP synthetisiert. Als Tetrazin-
Gegenstück wurde das stabile, aber dennoch reaktive dPG-metTet erhalten. Die 






verglichen. Die Gelierungszeiten wurden bestimmt und es zeigte sich, dass nur dPG-
Norbonen und dPG-Cyclopropen Makrogele bilden konnten, während dPG-BCN eine 
unvollständige und dPG-DHP überhaupt keine Gelbildung zeigte. Für die Nanogelbildung 
wurden Reaktionsparameter wie Rotationsgeschwindigkeit, Makromonomerkonzentration, 
Quenchzeiten und das Verhältnis von Lösungsmittel zu Nicht-Lösungsmittel untersucht. Das 
Verhältnis von Lösungsmittel zu Nicht-Lösungsmittel und die Quenchzeit waren hierbei die 
wichtigsten Parameter zur Beeinflussung der Größe des Nanogels, sowie dessen 
Polydispersität. Die Nanogele wurden, im für biomedizinische Anwendungen relevanten, 
Größenbereich von 40 bis 200 nm hergestellt und waren in wässriger Lösung mindestens 
mehrere Monate lang stabil. Die Co-Präzipitation des kleinen Modellproteins Myoglobin 
wurde mit den vielversprechendsten Makromonomerkandidaten dPG-Norbonen und -
Cyclopropen durchgeführt. Es wurden Verkapselungswirkungsgrade von über 70% erreicht. 
So konnte gezeigt werden, dass eine Kombination aus dPG als Polymergerüst, zusammen mit 
leicht erhältlichen iEDDA-reaktiven Gruppen wie Norbonen und Methyltetrazin, eine flexible 
Basis für skalierbare und funktionelle Nanotransporter für Proteine schafft. 
Die zweite Studie zielte darauf ab, die gewonnenen Erkenntnisse über die Parameter 
der Nanogelbildung, wie z.B. die Quenchzeit und das Verhältnis von Lösungsmittel zu Nicht-
Lösungsmittel auf eine bioabbaubare Version des Nanogelsystems zu übertragen. Die 
Abbaubarkeit wurde hierbei durch die Einführung von pH-spaltbaren Acetalgruppen erreicht. 
Es wurde ein Acetal verwendet, welches bei pH-Werten unter 5 (Benzacetal) spaltbar ist und 
eines, welches bei Werten unter 3 (THP) spaltet. Dazu wurde dPG mit den jeweiligen Acetal-
Linkern funktionalisiert und dann mit den Dienophilen Norbonen und BCN aus der ersten 
Studie weiter funktionalisiert. Norbonen hatte sich bereits in der vorangegangenen Studie als 
der vielversprechendste Kandidat herausgestellt und wurde mit dem gut etablierten Reagenz 
BCN verglichen. Die Makromonomere zeigten bis zu einer Konzentration von 2,5 mg/ml in 
drei verschiedenen Zelllinien keine Toxizität. Mit den genannten Makromonomeren war es 
möglich Nanogele im Größenbereich von 47-200 nm zu synthetisieren, welche in wässriger 
Lösung bei pH 7,4, ohne Zersetzung oder Erhöhung der Polydispersität über mehrere Monate 
stabil waren. Unter sauren Bedingungen hingegen spalteten sich die Nanogele auf 
Benzacetalbasis innerhalb von 48 Stunden bei pH 4,5 in kleine Partikel, während die 
Nanogele auf THP-Acetalbasis erst nach 48 Stunden bei pH 3 in kleine Partikel zerfielen. 
Dies bewies die Anwendbarkeit von Benzacetal-Nanogelen für die lysosomale Spaltung und 
intrazelluläre Freisetzung von Proteinen, während THP-Acetal Nanogele für eine mögliche 






Präzipitation des therapeutischen Proteins Asparaginase zeigte eine Verkapselungseffizienz 
von bis zu 93%.  
Die Abbaubarkeit der Gele, die hohen Verkapselungswirkungsgrade sowie die synthetische 
Zugänglichkeit und Biokompatibilität der Makromonomer-Vorstufen zeigen das Potenzial 
dieser Nanocarrier-Plattform für biomedizinische Anwendungen auf. 
Basierend auf den gewonnenen Daten ist das Potenzial der iEDDA-basierten Nanogele 
offensichtlich. Die Skalierbarkeit muss jedoch zumindest für die Nanogel-Produktion selbst 
verbessert werden. Kontinuierliche Produktionsmethoden, wie die mikrofluidische 
Nanopräzipitation, könnten potenziell für das Upscaling der in dieser Arbeit vorgestellten 
Nanogele eingesetzt werden. Darüber hinaus würde die Funktionalisierung der Nanogele mit 
Liganden für das aktive Targeting den Nutzen dieser Nanogele für biomedizinische 
Anwendungen noch weiter erhöhen. Eine Möglichkeit einer leicht zugänglichen aktiven 
Targeting-Funktionalität wäre die Sulfatierung der dPG-Makromonomere, welche eine L-
Selektin-Bindungsaffinität in die Nanogele einbringen würde. Damit könnte eine gezielte 
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8.1 List of Abbreviations 
API Active Pharmaceutical Ingredient 
BCA Bicinchoninic Acid 
BCN bicyclo[6.1.0]non-4-yne 
BSA Bovine Serum Albumin 
CMC Critical Micelle Concentration 
conc. Concentrated 




DLS Dynamic Light Scattering 
DMF N,N’-Dimethylformamide 
DANN Desoxyribonucleic Acid 
dPG Dendritic Polyglycerol 
EPR Enhanced Permeation and Retention Effect 
eq.  Equivalents 
ESI-MS Electron Spray Ionization Mass Spectrometry 
Et2O Diethylether 
EtOAc Ethyl Acetate 
EtOH Ethanol 
FDA Food and Drug Administration 
GPC Gel Permeation Chromatography 
GSH Gluthathion 
H Hour 
HATU Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium 
HOBt 1-hydroxybenzotriazol 
HOMO Highest Occupied Molecular Orbital 
HPLC High-Performance Liquid Chromatography 
Hz Hertz 






J  Coupling Constant 
LADMET Liberation Administration Distribution Metabolism Excretion Toxicity 
LCST Lower Critical Solution Temperature 
lPG Linear Polyglycerol 
LUMO Lowest Unoccupied Molecular Orbital 
MALDI-ToF Matrix Assisted Laser Desorption Ionization Time-of-Flight 
Me Methyl 
MeOH Methanol 
min(s)  Minute(s) 
MPS Mononuclear Phagocyte System 
MWCO Molecular Weight Cutoff 
NG Nanogel 
NMR Nuclear Magnetic Resonance 
NTA Nanoparticle Tracking Analysis 
PCL Polycaprolactone 
PDI Polydispersity Index 
PEG Polyethylene glycol 
PLA Polylactic Acid 
PLGA Polylactic-co-glycolic Acid 
PPI Polypropylene Imine 
ppm Parts Per Million 
PRINT Particle Replication In Non-wetting Templates 
PS Polystyrene 
PVA Polyvinyl Alcohol 
quant.  Quantitative 
r.t.  Room Temperature 
RNA Ribonucleic Acid 
SPAAC Strain-Promoted Azide Alkyne Cycloaddition 
THP Tetrahydropyran 
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